{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:15:37Z","timestamp":1785802537846,"version":"3.56.0"},"reference-count":297,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Extensive research in countries with high sociodemographic indices (SDIs) to date has shown that coronavirus disease 2019 (COVID-19) may be directly associated with more severe outcomes among patients living with haematological disorders and malignancies (HDMs). Because individuals with moderate to severe immunodeficiency are likely to undergo persistent infections, shed virus particles for prolonged periods, and lack an inflammatory or abortive phase, this represents an overall risk of morbidity and mortality from COVID-19. In cases suffering from HDMs, further investigation is needed to achieve a better understanding of triviruses and a group of related variants in patients with anemia and HDMs, as well as their treatment through vaccines, drugs, and other methods. Against this background, the present study aimed to delineate the relationship between HDMs and the novel COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Besides, effective treatment options for HDM cases were further explored to address this epidemic and its variants. Therefore, learning about how COVID-19 manifests in these patients, along with exploiting the most appropriate treatments, may lead to the development of treatment and care strategies by clinicians and researchers to help patients recover faster.<\/jats:p>","DOI":"10.1186\/s12964-023-01316-9","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T08:03:09Z","timestamp":1707984189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches"],"prefix":"10.1186","volume":"22","author":[{"given":"Sareh","family":"Kakavandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahareh","family":"Hajikhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paniz","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Aziziyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8243-1530","authenticated-orcid":false,"given":"Mohsen","family":"Nabi-Afjadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh Ramezani","family":"Farani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Zalpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Azarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdiyar Iravani","family":"Saadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrouz","family":"Gharesi-Fard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0056-5576","authenticated-orcid":false,"given":"Iman","family":"Zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Motamedifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"1316_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.htct.2021.11.015","volume":"44","author":"BA Costa","year":"2022","unstructured":"Costa BA, da Luz KV, Campos SEV, Lopes GS, Leit\u00e3o JP, Duarte FB (2022) Can SARS-CoV-2 induce hematologic malignancies in predisposed individuals? A case series and review of the literature. Hematol Transfus Cell Ther 44:26\u201331","journal-title":"Hematol Transfus Cell Ther"},{"key":"1316_CR2","first-page":"19","volume":"68","author":"A Aggarwal","year":"2020","unstructured":"Aggarwal A, Shrivastava A, Kumar A, Ali A (2020) Clinical and epidemiological features of SARS-CoV-2 patients in SARI ward of a tertiary care centre in New Delhi. J Assoc Physicians India. 68:19\u201326","journal-title":"J Assoc Physicians India."},{"key":"1316_CR3","unstructured":"GenScript Rare Codon Analysis Tool, http:\/\/www.genscript.com\/cgi-bin\/tools\/rare_codon_analysis. 2014."},{"key":"1316_CR4","doi-asserted-by":"publisher","first-page":"105955","DOI":"10.1016\/j.ijantimicag.2020.105955","volume":"55","author":"P Zhai","year":"2020","unstructured":"Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y (2020) The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 55:105955","journal-title":"Int J Antimicrob Agents"},{"key":"1316_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.abst.2020.08.001","volume":"2","author":"L Zhang","year":"2020","unstructured":"Zhang L, Guo H (2020) Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. Adv Biomark Sci Technol 2:1\u201323","journal-title":"Adv Biomark Sci Technol"},{"key":"1316_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00277-020-04256-3","volume":"100","author":"AA Algassim","year":"2021","unstructured":"Algassim AA, Elghazaly AA, Alnahdi AS, Mohammed-Rahim OM, Alanazi AG, Aldhuwayhi NA, Alanazi MM, Almutairi MF, Aldeailej IM, Kamli NA (2021) Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection. Ann Hematol 100:37\u201343","journal-title":"Ann Hematol"},{"key":"1316_CR7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s10654-020-00678-5","volume":"35","author":"PE Taneri","year":"2020","unstructured":"Taneri PE, G\u00f3mez-Ochoa SA, Llanaj E, Raguindin PF, Rojas LZ, Roa-D\u00edaz ZM, Salvador D, Groothof D, Minder B, Kopp-Heim D (2020) Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol 35:763\u2013773","journal-title":"Eur J Epidemiol"},{"key":"1316_CR8","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s00277-022-04833-8","volume":"101","author":"R Taenaka","year":"2022","unstructured":"Taenaka R, Obara T, Kohno K, Aoki K, Ogawa R (2022) Infections with the SARS-CoV-2 Omicron variant show a similar outcome as infections with the previous variants in patients with hematologic malignancies. Ann Hematol 101:1877\u20131878","journal-title":"Ann Hematol"},{"key":"1316_CR9","doi-asserted-by":"crossref","unstructured":"Miller MA, Zachary JF. Mechanisms and morphology of cellular injury, adaptation, and death. Pathol Basis Vet Dis. 2017;2\u201343.e19.","DOI":"10.1016\/B978-0-323-35775-3.00001-1"},{"key":"1316_CR10","doi-asserted-by":"publisher","first-page":"111228","DOI":"10.1016\/j.biopha.2021.111228","volume":"136","author":"HM Habib","year":"2021","unstructured":"Habib HM, Ibrahim S, Zaim A, Ibrahim WH (2021) The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators. Biomed Pharmacother 136:111228","journal-title":"Biomed Pharmacother"},{"key":"1316_CR11","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3390\/cancers12082237","volume":"12","author":"S Vivarelli","year":"2020","unstructured":"Vivarelli S, Falzone L, Grillo CM, Scandurra G, Torino F, Libra M (2020) Cancer management during COVID-19 pandemic: is immune checkpoint inhibitors-based immunotherapy harmful or beneficial? Cancers 12:2237","journal-title":"Cancers"},{"key":"1316_CR12","doi-asserted-by":"publisher","first-page":"100775","DOI":"10.1016\/j.blre.2020.100775","volume":"47","author":"Q Wang","year":"2021","unstructured":"Wang Q, Berger NA, Xu R (2021) When hematologic malignancies meet COVID-19 in the United States: infections, death and disparities. Blood Rev 47:100775","journal-title":"Blood Rev"},{"key":"1316_CR13","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/15257770.2022.2071937","volume":"41","author":"KV Nguyen","year":"2022","unstructured":"Nguyen KV (2022) Containing the spread of COVID-19 virus facing to its high mutation rate: approach to intervention using a nonspecific way of blocking its entry into the cells. Nucleosides Nucleotides Nucleic Acids 41:778\u2013814","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"1316_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/joim.13372","volume":"291","author":"X Castro Dopico","year":"2022","unstructured":"Castro Dopico X, Ols S, Lor\u00e9 K, Karlsson Hedestam GB (2022) Immunity to SARS-CoV-2 induced by infection or vaccination. J Intern Med 291:32\u201350","journal-title":"J Intern Med"},{"key":"1316_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/14787210.2022.2089653","volume":"20","author":"DS Mouliou","year":"2022","unstructured":"Mouliou DS (2022) Managing viral emerging infectious diseases via current molecular diagnostics in the emergency department: the tricky cases. Expert Rev Anti Infect Ther 20:1163\u20131169","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1316_CR16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/17476348.2021.1917389","volume":"15","author":"DS Mouliou","year":"2021","unstructured":"Mouliou DS, Gourgoulianis KI (2021) False-positive and false-negative COVID-19 cases: respiratory prevention and management strategies, vaccination, and further perspectives. Expert Revi Respir Med 15:993\u20131002","journal-title":"Expert Revi Respir Med"},{"key":"1316_CR17","doi-asserted-by":"publisher","first-page":"106514","DOI":"10.1016\/j.leukres.2021.106514","volume":"101","author":"M Ibrahim","year":"2021","unstructured":"Ibrahim M, Vegel A, Niu A, Panse K, Chen R, Safah H, Socola F, Luk A, Saba NS (2021) Reinfection versus failure of viral clearance in a COVID-19 patient with hematologic malignancy. Leukemia Res 101:106514","journal-title":"Leukemia Res"},{"key":"1316_CR18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/ejh.13491","volume":"105","author":"C Agbuduwe","year":"2020","unstructured":"Agbuduwe C, Basu S (2020) Haematological manifestations of COVID-19: from cytopenia to coagulopathy. Eur J Haematol 105:540\u2013546","journal-title":"Eur J Haematol"},{"key":"1316_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/ajh.26384","volume":"97","author":"E Korompoki","year":"2022","unstructured":"Korompoki E, Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E (2022) Late-onset hematological complications post COVID-19: an emerging medical problem for the hematologist. Am J Hematol 97:119\u2013128","journal-title":"Am J Hematol"},{"key":"1316_CR20","doi-asserted-by":"publisher","first-page":"e0283983","DOI":"10.1371\/journal.pone.0283983","volume":"18","author":"SM Gomes","year":"2023","unstructured":"Gomes SM, Brito AC, Manfro WF, Ribeiro-Alves M, Ribeiro RS, da Cal MS, Lisboa VD, Abreu DP, Castilho LD, Porto LC (2023) High levels of pro-inflammatory SARS-CoV-2-specific biomarkers revealed by in vitro whole blood cytokine release assay (CRA) in recovered and long-COVID-19 patients. Plos one 18:e0283983","journal-title":"Plos one"},{"key":"1316_CR21","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3324\/haematol.2019.232124","volume":"105","author":"C Camaschella","year":"2020","unstructured":"Camaschella C, Nai A, Silvestri L (2020) Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica 105:260","journal-title":"Haematologica"},{"key":"1316_CR22","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1590\/1806-9282.20210555","volume":"67","author":"EMB Mancilha","year":"2021","unstructured":"Mancilha EMB, Oliveira JS (2021) SARS-CoV-2 association with hemoglobin and iron metabolism. Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira 67:1349\u20131352","journal-title":"Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"},{"key":"1316_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399406010805","volume":"8","author":"F Urbinati","year":"2006","unstructured":"Urbinati F, Madigan C, Malik P (2006) Pathophysiology and therapy for haemoglobinopathies; part II: thalassaemias. Expert Rev Mol Med 8:1\u201326","journal-title":"Expert Rev Mol Med"},{"key":"1316_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/thalassrep13010003","volume":"13","author":"E Lansiaux","year":"2023","unstructured":"Lansiaux E, Drouin E, Bolm C (2023) Beta-thalassemia minor and SARS-CoV-2: physiopathology, prevalence, severity, morbidity, and mortality. Thalassemia Rep 13:21\u201332","journal-title":"Thalassemia Rep"},{"key":"1316_CR25","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3390\/antiox9070636","volume":"9","author":"EW Fakhouri","year":"2020","unstructured":"Fakhouri EW, Peterson SJ, Kothari J, Alex R, Shapiro JI, Abraham NG (2020) Genetic polymorphisms complicate COVID-19 therapy: pivotal role of HO-1 in cytokine storm. Antioxidants 9:636","journal-title":"Antioxidants"},{"key":"1316_CR26","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1172\/JCI21982","volume":"114","author":"Y Kong","year":"2004","unstructured":"Kong Y, Zhou S, Kihm AJ, Katein AM, Yu X, Gell DA, Mackay JP, Adachi K, Foster-Brown L, Louden CS (2004) Loss of \u03b1-hemoglobin\u2013stabilizing protein impairs erythropoiesis and exacerbates \u03b2-thalassemia. J Clin Investig 114:1457\u20131466","journal-title":"J Clin Investig"},{"key":"1316_CR27","first-page":"113","volume":"85","author":"JA Stockman","year":"1975","unstructured":"Stockman JA, Weiner LS, Simon GE, Stuart MJ, Oski FA (1975) The measurement of free erythrocyte porphyrin (FEP) as a simple means of distinguishing iron deficiency from beta-thalassemia trait in subjects with microcytosis. J Lab Clin Med 85:113\u2013119","journal-title":"J Lab Clin Med"},{"key":"1316_CR28","doi-asserted-by":"crossref","unstructured":"Sotiriou S, Samara AA, Lachanas KE, Vamvakopoulou D, Vamvakopoulos KO, Vamvakopoulos N, Janho MB, Perivoliotis K, Donoudis C, Daponte A, Gourgoulianis KI (2022) Vulnerability of \u03b2-thalassemia heterozygotes to COVID-19: results from a cohort study. J Pers Med 12:352","DOI":"10.3390\/jpm12030352"},{"key":"1316_CR29","first-page":"27","volume":"20","author":"AJ Marengo-Rowe","year":"2007","unstructured":"Marengo-Rowe AJ (2007) The thalassemias and related disorders. Proc (Bayl Univ Med Cent) 20:27\u201331","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"1316_CR30","doi-asserted-by":"crossref","unstructured":"Teulier M, Elabbadi A, Gerotziafas G, Lionnet F, Voiriot G, Fartoukh M (2021) Severe COVID-19 with acute respiratory distress syndrome (ARDS) in a sickle cell disease adult patient: case report. BMC Pulm Med 21:1\u20135","DOI":"10.1186\/s12890-021-01412-x"},{"key":"1316_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1076029620955240","volume":"26","author":"F Alsayegh","year":"2020","unstructured":"Alsayegh F, Mousa SA (2020) Challenges in the management of sickle cell disease during SARS-CoV-2 pandemic. Clin Appl Thromb Hemost 26:1\u20138","journal-title":"Clin Appl Thromb Hemost"},{"key":"1316_CR32","first-page":"e23604","volume":"14","author":"Z Umar","year":"2022","unstructured":"Umar Z, Ilyas U, Nso N (2022) Sickle cell disease and COVID-19 infection: importance of COVID-19 testing and approach to management. Cureus 14:e23604","journal-title":"Cureus"},{"key":"1316_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1365-2141.2005.05432.x","volume":"129","author":"RF Machado","year":"2005","unstructured":"Machado RF, Gladwin MT (2005) Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol 129:449\u2013464","journal-title":"Br J Haematol"},{"key":"1316_CR34","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3390\/biomedicines11020338","volume":"11","author":"KC Chiang","year":"2023","unstructured":"Chiang KC, Gupta A, Sundd P, Krishnamurti L (2023) Thrombo-inflammation in COVID-19 and sickle cell disease: two faces of the same coin. Biomedicines 11:338","journal-title":"Biomedicines"},{"key":"1316_CR35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/jha2.105","volume":"1","author":"T Sivalingam","year":"2020","unstructured":"Sivalingam T, Inusa B, Doyle P, Oteng-Ntim E (2020) COVID-19 and the pulmonary complications of sickle cell disease. EJHaem 1:545\u2013547","journal-title":"EJHaem"},{"key":"1316_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4103\/jnsm.jnsm_49_21","volume":"5","author":"A Alhazmi","year":"2022","unstructured":"Alhazmi A, Moafa WA, Madkhali J, Saifain O, Alyahyawi F, Adhabi O, Alharbi AA (2022) Coronavirus disease 2019 in patients with sickle cell disease: a cross-sectional study from Jazan Province, Saudi Arabia. J Nat Sci Med 5:199","journal-title":"J Nat Sci Med"},{"key":"1316_CR37","doi-asserted-by":"publisher","first-page":"104647","DOI":"10.1016\/j.meegid.2020.104647","volume":"87","author":"SK Alyammahi","year":"2021","unstructured":"Alyammahi SK, Abdin SM, Alhamad DW, Elgendy SM, Altell AT, Omar HA (2021) The dynamic association between COVID-19 and chronic disorders: an updated insight into prevalence, mechanisms and therapeutic modalities. Infect Genet Evol 87:104647","journal-title":"Infect Genet Evol"},{"key":"1316_CR38","doi-asserted-by":"publisher","first-page":"100911","DOI":"10.1016\/j.blre.2021.100911","volume":"53","author":"WS Hoogenboom","year":"2022","unstructured":"Hoogenboom WS, Alamuri TT, McMahon DM, Balanchivadze N, Dabak V, Mitchell WB, Morrone KB, Manwani D, Duong TQ (2022) Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: a critical appraisal of the literature. Blood Rev 53:100911","journal-title":"Blood Rev"},{"key":"1316_CR39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12964-023-01104-5","volume":"21","author":"S Kakavandi","year":"2023","unstructured":"Kakavandi S, Zare I, VaezJalali M, Dadashi M, Azarian M, Akbari A, Ramezani Farani M, Zalpoor H, Hajikhani B (2023) Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases. Cell Commun Signal 21:110","journal-title":"Cell Commun Signal"},{"key":"1316_CR40","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00702-010-0479-3","volume":"118","author":"RJ Ward","year":"2011","unstructured":"Ward RJ, Crichton RR, Taylor DL, Corte LD, Srai SK, Dexter DT (2011) Iron and the immune system. J Neural Transm 118:315\u2013328","journal-title":"J Neural Transm"},{"key":"1316_CR41","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M (2021) Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol 22:266\u2013282","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1316_CR42","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molcel.2021.12.001","volume":"82","author":"R Rodriguez","year":"2022","unstructured":"Rodriguez R, Schreiber SL, Conrad M (2022) Persister cancer cells: Iron addiction and vulnerability to ferroptosis. Mol Cell 82:728\u2013740","journal-title":"Mol Cell"},{"key":"1316_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mito.2023.05.003","volume":"71","author":"SP Panda","year":"2023","unstructured":"Panda SP, Kesharwani A (2023) Micronutrients\/miRs\/ATP networking in mitochondria: clinical intervention with ferroptosis, cuproptosis, and calcium burden. Mitochondrion 71:1\u201316","journal-title":"Mitochondrion"},{"key":"1316_CR44","doi-asserted-by":"publisher","first-page":"102537","DOI":"10.1016\/j.autrev.2020.102537","volume":"19","author":"D McGonagle","year":"2020","unstructured":"McGonagle D, Sharif K, O\u2019Regan A, Bridgewood C (2020) The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 19:102537","journal-title":"Autoimmun Rev"},{"key":"1316_CR45","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev.nutr.26.061505.111303","volume":"26","author":"E Nemeth","year":"2006","unstructured":"Nemeth E, Ganz T (2006) Regulation of iron metabolism by hepcidin. Annu Rev Nutr 26:323\u2013342","journal-title":"Annu Rev Nutr"},{"key":"1316_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.643686","volume":"8","author":"E Wlazlo","year":"2021","unstructured":"Wlazlo E, Mehrad B, Morel L, Scindia Y (2021) Iron metabolism: an under investigated driver of renal pathology in lupus nephritis. Frontiers in Medicine. 8:643686","journal-title":"Frontiers in Medicine."},{"key":"1316_CR47","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.3390\/ijms22094591","volume":"22","author":"A-CS Vogt","year":"2021","unstructured":"Vogt A-CS, Arsiwala T, Mohsen M, Vogel M, Manolova V, Bachmann MF (2021) On iron metabolism and its regulation. Int J Mol Sci 22:4591","journal-title":"Int J Mol Sci"},{"key":"1316_CR48","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.3390\/jcm9082429","volume":"9","author":"R Bellmann-Weiler","year":"2020","unstructured":"Bellmann-Weiler R, Lanser L, Barket R, Rangger L, Schapfl A, Schaber M, Fritsche G, W\u00f6ll E, Weiss G (2020) Prevalence and predictive value of anemia and dysregulated iron homeostasis in patients with COVID-19 infection. J Clin Med 9:2429","journal-title":"J Clin Med"},{"key":"1316_CR49","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1016\/j.clnu.2020.11.033","volume":"40","author":"Y Lv","year":"2021","unstructured":"Lv Y, Chen L, Liang X, Liu X, Gao M, Wang Q, Wei Q, Liu L (2021) Association between iron status and the risk of adverse outcomes in COVID-19. Clin Nutr 40:3462\u20133469","journal-title":"Clin Nutr"},{"key":"1316_CR50","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1055\/s-0040-1712181","volume":"37","author":"L Shi","year":"2020","unstructured":"Shi L, Wang Y, Yang H, Duan G, Wang Y (2020) Laboratory abnormalities in pregnant women with novel coronavirus disease 2019. Am J Perinatol 37:1070\u20131073","journal-title":"Am J Perinatol"},{"key":"1316_CR51","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.3390\/nu14153090","volume":"14","author":"JL Ward","year":"2022","unstructured":"Ward JL, Torres-Gonzalez M, Ammons MCB (2022) The influence of viral infections on iron homeostasis and the potential for lactoferrin as a therapeutic in the age of the SARS-CoV-2 pandemic. Nutrients 14:3090","journal-title":"Nutrients"},{"key":"1316_CR52","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1007\/s12015-021-10322-8","volume":"18","author":"R Kronstein-Wiedemann","year":"2022","unstructured":"Kronstein-Wiedemann R, Stadtm\u00fcller M, Traikov S, Georgi M, Teichert M, Yosef H, Wallenborn J, Karl A, Sch\u00fctze K, Wagner M (2022) SARS-CoV-2 Infects red blood cell progenitors and dysregulates hemoglobin and iron metabolism. Stem Cell Rev Rep 18:1809\u20131821","journal-title":"Stem Cell Rev Rep"},{"key":"1316_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1741-7015-11-185","volume":"11","author":"C Ros\u00e1rio","year":"2013","unstructured":"Ros\u00e1rio C, Zandman-Goddard G, Meyron-Holtz EG, D\u2019Cruz DP, Shoenfeld Y (2013) The hyperferritinemic syndrome: macrophage activation syndrome, Still\u2019s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med 11:1\u201311","journal-title":"BMC Med"},{"key":"1316_CR54","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.2174\/1381612825666190709202804","volume":"25","author":"J Giemza-Stok\u0142osa","year":"2019","unstructured":"Giemza-Stok\u0142osa J, Islam MA, Kotyla PJ (2019) Hyperferritinaemia: an iron sword of autoimmunity. Curr Pharm Des 25:2909\u20132918","journal-title":"Curr Pharm Des"},{"key":"1316_CR55","first-page":"451","volume":"9","author":"V Sumbly","year":"2021","unstructured":"Sumbly V, Siddiqui R, Alshamam M, Kurbanova T, Rizzo V (2021) New onset aplastic anemia after a COVID-19 infection: a case report. Am J Med Case Rep 9:451\u2013455","journal-title":"Am J Med Case Rep"},{"key":"1316_CR56","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/ejh.13153","volume":"101","author":"RM Shallis","year":"2018","unstructured":"Shallis RM, Ahmad R, Zeidan AM (2018) Aplastic anemia: etiology, molecular pathogenesis, and emerging concepts. Eur J Haematol 101:711\u2013720","journal-title":"Eur J Haematol"},{"key":"1316_CR57","first-page":"19","volume":"2","author":"I Khalid","year":"2022","unstructured":"Khalid I, Abbas F, Mustafa Z, Kamran M (2022) Association of various etiological factors with idiopathic acquired aplastic anemia. J Haematol Stem Cell Res 2:19\u201325","journal-title":"J Haematol Stem Cell Res"},{"key":"1316_CR58","first-page":"e12174","volume":"12","author":"E Shehi","year":"2020","unstructured":"Shehi E, Ghazanfar H, Fortuzi K, Gonzalez E, Zeana C (2020) A rare case of parvovirus B19 infection manifesting as chronic aplastic anemia and neutropenia in a human immunodeficiency virus-infected patient. Cureus 12:e12174","journal-title":"Cureus"},{"key":"1316_CR59","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1182\/blood-2006-09-045625","volume":"109","author":"P Scheinberg","year":"2007","unstructured":"Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM, Cohen JI, Young NS, John Barrett A (2007) Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 109:3219\u20133224","journal-title":"Blood"},{"key":"1316_CR60","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/rmv.1839","volume":"25","author":"JR Kerr","year":"2015","unstructured":"Kerr JR (2015) A review of blood diseases and cytopenias associated with human parvovirus B19 infection. Rev Med Virol 25:224\u2013240","journal-title":"Rev Med Virol"},{"key":"1316_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-023-01122-3","volume":"21","author":"K Nasiri","year":"2023","unstructured":"Nasiri K, Mohammadzadehsaliani S, Kheradjoo H, Shabestari AM, Eshaghizadeh P, Pakmehr A, Alsaffar MF, Al-Naqeeb BZT, Yasamineh S, Gholizadeh O (2023) Spotlight on the impact of viral infections on Hematopoietic Stem Cells (HSCs) with a focus on COVID-19 effects. Cell Commun Signal 21:1\u201315","journal-title":"Cell Commun Signal"},{"key":"1316_CR62","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","volume":"184","author":"R Karki","year":"2021","unstructured":"Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, Zheng M, Sundaram B, Banoth B, Malireddi RS (2021) Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184:149\u2013168","journal-title":"Cell"},{"key":"1316_CR63","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/sj.leu.2400844","volume":"11","author":"M Kitagawa","year":"1997","unstructured":"Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, Tanizawa T, Kamiyama R, Hirokawa K (1997) Overexpression of tumor necrosis factor (TNF)-\u03b1 and interferon (IFN)-\u03b3 by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 11:2049\u20132054","journal-title":"Leukemia"},{"key":"1316_CR64","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0378-5122(96)01080-8","volume":"26","author":"S Zheng","year":"1997","unstructured":"Zheng S, Vrindts Y, Lopez M, De Groote D, Zangerl\u00e9 P-F, Collette J, Franchimont N, Geenen V, Albert A, Reginster J-Y (1997) Increase in cytokine production (IL-1\u03b2, IL-6, TNF-\u03b1 but not IFN-\u03b3, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas 26:63\u201371","journal-title":"Maturitas"},{"key":"1316_CR65","doi-asserted-by":"publisher","first-page":"eabf0113","DOI":"10.1126\/scitranslmed.abf0113","volume":"13","author":"D Iskander","year":"2021","unstructured":"Iskander D, Wang G, Heuston EF, Christodoulidou C, Psaila B, Ponnusamy K, Ren H, Mokhtari Z, Robinson M, Chaidos A (2021) Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia. Sci Transl Med 13:eabf0113","journal-title":"Sci Transl Med"},{"key":"1316_CR66","doi-asserted-by":"publisher","first-page":"78","DOI":"10.12968\/bjha.2021.15.2.78","volume":"15","author":"C Barber","year":"2021","unstructured":"Barber C (2021) Rare health conditions 44: ataxia, Diamond Blackfan anaemia, sexual identities. Br J Healthcare Assist 15:78\u201383","journal-title":"Br J Healthcare Assist"},{"key":"1316_CR67","doi-asserted-by":"crossref","unstructured":"Wenzhong, Liu, and Li Hualan (2020) COVID-19: attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv Preprint","DOI":"10.26434\/chemrxiv.11938173"},{"key":"1316_CR68","doi-asserted-by":"crossref","unstructured":"Dutt S, Hamza I, Bartnikas TB (2022) Molecular mechanisms of iron and heme metabolism. Annu Rev Nutr 42:311\u201335","DOI":"10.1146\/annurev-nutr-062320-112625"},{"key":"1316_CR69","doi-asserted-by":"crossref","unstructured":"Lee JX, Chieng WK, Lau SC, Tan CE (2021) COVID-19 and hemoglobinopathies: a systematic review of clinical presentations, investigations, and outcomes. Front Med 8:757510","DOI":"10.3389\/fmed.2021.757510"},{"key":"1316_CR70","doi-asserted-by":"publisher","first-page":"e28548","DOI":"10.1002\/pbc.28548","volume":"68","author":"T Severance","year":"2021","unstructured":"Severance T, Rahim M, French J, Baker R, Shriner A, Khaitan A, Overholt K (2021) COVID-19 and hereditary spherocytosis: a recipe for hemolysis. Pediatr Blood Cancer 68:e28548","journal-title":"Pediatr Blood Cancer"},{"key":"1316_CR71","doi-asserted-by":"publisher","first-page":"e28337","DOI":"10.1002\/pbc.28337","volume":"67","author":"JA Rothman","year":"2020","unstructured":"Rothman JA, Stevens JL, Gray FL, Kalfa TA (2020) How I approach hereditary hemolytic anemia and splenectomy. Pediatr Blood Cancer 67:e28337","journal-title":"Pediatr Blood Cancer"},{"key":"1316_CR72","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1001\/archsurg.1970.01340260242036","volume":"101","author":"SI Schwartz","year":"1970","unstructured":"Schwartz SI, Bernard RP, Adams JT, Bauman AW (1970) Splenectomy for hematologic disorders. Arch Surg 101:338\u2013347","journal-title":"Arch Surg"},{"key":"1316_CR73","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jpedsurg.2010.09.090","volume":"46","author":"KL Buesing","year":"2011","unstructured":"Buesing KL, Tracy ET, Kiernan C, Pastor AC, Cassidy LD, Scott JP, Ware RE, Davidoff AM, Rescorla FJ, Langer JC (2011) Partial splenectomy for hereditary spherocytosis: a multi-institutional review. J Pediatr Surg 46:178\u2013183","journal-title":"J Pediatr Surg"},{"key":"1316_CR74","doi-asserted-by":"publisher","first-page":"110","DOI":"10.21614\/chirurgia.112.2.110","volume":"112","author":"S Manciu","year":"2017","unstructured":"Manciu S, Matei E, Trandafir B (2017) Hereditary spherocytosis-diagnosis, surgical treatment and outcomes. A literature review. Chirurgia (Bucur) 112:110\u2013116","journal-title":"Chirurgia (Bucur)"},{"key":"1316_CR75","doi-asserted-by":"crossref","unstructured":"Severance T, Rahim M, French J, Baker R, Shriner A, Khaitan A, Overholt K (2020) COVID-19 and hereditary spherocytosis: a recipe for hemolysis. Authorea Preprints","DOI":"10.22541\/au.159069398.87906649"},{"key":"1316_CR76","doi-asserted-by":"publisher","first-page":"102","DOI":"10.12688\/f1000research.108667.2","volume":"11","author":"A Cavezzi","year":"2022","unstructured":"Cavezzi A, Menicagli R, Troiani E, Corrao S (2022) COVID-19, cation dysmetabolism, sialic acid, CD147, ACE2, viroporins, hepcidin and ferroptosis: a possible unifying hypothesis. F1000Research 11:102","journal-title":"F1000Research"},{"key":"1316_CR77","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/ajh.25793","volume":"95","author":"A Mitra","year":"2020","unstructured":"Mitra A, Dwyre DM, Schivo M, Thompson GR III, Cohen SH, Ku N, Graff JP (2020) Leukoerythroblastic reaction in a patient with COVID-19 infection. Am J Hematol 95:999\u20131000","journal-title":"Am J Hematol"},{"key":"1316_CR78","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/ijlh.13238","volume":"42","author":"E Tabares Calvache","year":"2020","unstructured":"Tabares Calvache E, Tabares Calvache AD, Faulhaber GAM (2020) Systematic review about etiologic association to the leukoerythroblastic reaction. Int J Lab Hematol 42:495\u2013500","journal-title":"Int J Lab Hematol"},{"key":"1316_CR79","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1182\/blood.V65.4.803.803","volume":"65","author":"BC Wolf","year":"1985","unstructured":"Wolf BC, Neiman RS (1985) Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood 65:803\u2013809","journal-title":"Blood"},{"key":"1316_CR80","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","volume":"54","author":"VJ Costela-Ruiz","year":"2020","unstructured":"Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodr\u00edguez L (2020) SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev 54:62\u201375","journal-title":"Cytokine Growth Factor Rev"},{"key":"1316_CR81","doi-asserted-by":"crossref","unstructured":"Lee WS, Margolskee E (2020) Leukoerythroblastosis and plasmacytoid lymphocytes in a child with SARS-CoV-2\u2013associated multisystem inflammatory syndrome. Blood 136(7):914","DOI":"10.1182\/blood.2020007132"},{"key":"1316_CR82","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1586\/eri.09.109","volume":"8","author":"AH Rowley","year":"2010","unstructured":"Rowley AH, Shulman ST (2010) Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther 8:197\u2013203","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1316_CR83","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1161\/01.CIR.87.5.1776","volume":"87","author":"AS Dajani","year":"1993","unstructured":"Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, Takahashi M, Bierman FZ, Karchmer AW, Wilson W (1993) Diagnosis and therapy of Kawasaki disease in children. Circulation 87:1776\u20131780","journal-title":"Circulation"},{"key":"1316_CR84","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1086\/428291","volume":"191","author":"F Esper","year":"2005","unstructured":"Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS (2005) Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 191:499\u2013502","journal-title":"J Infect Dis"},{"key":"1316_CR85","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00296-020-04636-y","volume":"41","author":"M Soy","year":"2021","unstructured":"Soy M, Atag\u00fcnd\u00fcz P, Atag\u00fcnd\u00fcz I, Sucak GT (2021) Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic. Rheumatol Int 41:7\u201318","journal-title":"Rheumatol Int"},{"key":"1316_CR86","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12185-020-02895-w","volume":"112","author":"GG Loscocco","year":"2020","unstructured":"Loscocco GG (2020) Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19. Int J Hematol 112:125\u2013126","journal-title":"Int J Hematol"},{"key":"1316_CR87","first-page":"10807","volume":"25","author":"KS Kiran","year":"2021","unstructured":"Kiran KS, Yasitha K, Panakala S, Pitcairn N, Tiwari RV, Sharma M, Tiwari H (2021) Role of C-reactive protein, serum ferritin and D-Dimer in Covid cases: systematic review & meta analysis. Ann Romanian Soc Cell Biol 25:10807\u201310816","journal-title":"Ann Romanian Soc Cell Biol"},{"key":"1316_CR88","doi-asserted-by":"publisher","first-page":"832394","DOI":"10.3389\/fimmu.2022.832394","volume":"13","author":"R-J Hsu","year":"2022","unstructured":"Hsu R-J, Yu W-C, Peng G-R, Ye C-H, Hu S, Chong PCT, Yap KY, Lee JYC, Lin W-C, Yu S-H (2022) The role of cytokines and chemokines in severe acute respiratory syndrome coronavirus 2 infections. Front Immunol 13:832394","journal-title":"Front Immunol"},{"key":"1316_CR89","doi-asserted-by":"publisher","first-page":"316","DOI":"10.7150\/thno.49713","volume":"11","author":"JS Kim","year":"2021","unstructured":"Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szpirt W, Kronbichler A, Shin JI (2021) Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics 11:316","journal-title":"Theranostics"},{"key":"1316_CR90","doi-asserted-by":"crossref","unstructured":"Bordbar M, Sanaei Dashti A, Amanati A, Shorafa E, Mansoori Y, Dehghani SJ, Molavi Vardanjani H (2021) Assessment of the HScore as a predictor of disease outcome in patients with COVID-19. BMC Pulm Med 21:1-9","DOI":"10.1186\/s12890-021-01706-0"},{"key":"1316_CR91","first-page":"305","volume":"25","author":"G Abu-Zeinah","year":"2021","unstructured":"Abu-Zeinah G, DeSancho MT (2020) Understanding sideroblastic anemia: an overview of genetics, epidemiology, pathophysiology and current therapeutic options. J Blood Med 25:305-18","journal-title":"J Blood Med"},{"key":"1316_CR92","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.mrrev.2018.06.003","volume":"777","author":"P Brissot","year":"2018","unstructured":"Brissot P, Bernard DG, Brissot E, Lor\u00e9al O, Troadec M-B (2018) Rare anemias due to genetic iron metabolism defects. Mutat Res Rev Mutat Res 777:52\u201363","journal-title":"Mutat Res Rev Mutat Res"},{"key":"1316_CR93","first-page":"e30275","volume":"14","author":"N Mukhi","year":"2022","unstructured":"Mukhi N, Soto LR, Vuppala A (2022) Transient sideroblastic anemia post-COVID-19 infection. Cureus 14:e30275","journal-title":"Cureus"},{"key":"1316_CR94","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1007\/s11033-022-07226-2","volume":"49","author":"EM El-Sayed","year":"2022","unstructured":"El-Sayed EM, Ibrahim KS (2022) Ameliorating effects of probiotics on alterations in iron homeostasis and inflammation in COVID-19. Mol Biol R 49:5153\u20135163","journal-title":"Mol Biol R"},{"key":"1316_CR95","first-page":"e36247","volume":"15","author":"M Ayyashi","year":"2023","unstructured":"Ayyashi M, Darbashi H, Hakami A, Sharahili F, Sharahili F Sr (2023) Evaluation of remdesivir utilization pattern in critically Ill patients with COVID-19 in Jazan Province. Cureus 15:e36247","journal-title":"Cureus"},{"key":"1316_CR96","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.mayocpiqo.2019.03.002","volume":"3","author":"BH Wolffenbuttel","year":"2019","unstructured":"Wolffenbuttel BH, Wouters HJ, Heiner-Fokkema MR, van der Klauw MM (2019) The many faces of cobalamin (vitamin B12) deficiency. Mayo Clin Proc Innov Qual Outcomes 3:200\u2013214","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"1316_CR97","doi-asserted-by":"crossref","unstructured":"Allen LH. Efficacy and safety of vitamin B12 fortification. In: Food Fortification in a Globalized World. Elsevier. 2018:255-261.","DOI":"10.1016\/B978-0-12-802861-2.00026-2"},{"key":"1316_CR98","doi-asserted-by":"publisher","first-page":"127044","DOI":"10.1016\/j.jtemb.2022.127044","volume":"73","author":"MK Fath","year":"2022","unstructured":"Fath MK, Naderi M, Hamzavi H, Ganji M, Shabani S, Khalesi B, Pourzardosht N, Hashemi ZS, Khalili S (2022) Molecular Mechanisms and therapeutic effects of different vitamins and minerals in COVID-19 patients. J Trace Elem Med Biol 73:127044","journal-title":"J Trace Elem Med Biol"},{"key":"1316_CR99","doi-asserted-by":"publisher","first-page":"102717","DOI":"10.1016\/j.transci.2019.102717","volume":"59","author":"W Sabry","year":"2020","unstructured":"Sabry W, Elemary M, Burnouf T, Seghatchian J, Goubran H (2020) Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA). Transfus Apher Sci 59:102717","journal-title":"Transfus Apher Sci"},{"key":"1316_CR100","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s00467-016-3348-y","volume":"31","author":"MB Stokes","year":"2016","unstructured":"Stokes MB, Zviti R, Lin F, D\u2019Agati VD (2016) An unusual cause of hypertension with hematuria and proteinuria: answers. Pediatr Nephrol 31:2265\u20132270","journal-title":"Pediatr Nephrol"},{"key":"1316_CR101","doi-asserted-by":"publisher","first-page":"111017","DOI":"10.1016\/j.nut.2020.111017","volume":"79","author":"CW Tan","year":"2020","unstructured":"Tan CW, Ho LP, Kalimuddin S, Cherng BPZ, Teh YE, Thien SY, Wong HM, Tern PJW, Chandran M, Chay JWM (2020) Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). Nutrition 79:111017","journal-title":"Nutrition"},{"key":"1316_CR102","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1056\/NEJMcp1113996","volume":"368","author":"SP Stabler","year":"2013","unstructured":"Stabler SP (2013) Vitamin B12 deficiency. N Engl J Med 368:149\u2013160","journal-title":"N Engl J Med"},{"key":"1316_CR103","first-page":"1","volume":"3","author":"R Green","year":"2017","unstructured":"Green R, Allen LH, Bj\u00f8rke-Monsen A-L, Brito A, Gu\u00e9ant J-L, Miller JW, Molloy AM, Nexo E, Stabler S, Toh B-H (2017) Vitamin B12 deficiency. Nat Rev Dis Primers 3:1\u201320","journal-title":"Nat Rev Dis Primers"},{"key":"1316_CR104","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/bs.vh.2022.01.016","volume":"119","author":"J-L Gu\u00e9ant","year":"2022","unstructured":"Gu\u00e9ant J-L, Gu\u00e9ant-Rodriguez R-M, Alpers DH (2022) Vitamin B12 absorption and malabsorption. Vitam Horm 119:241\u2013274 (Elsevier)","journal-title":"Vitam Horm"},{"key":"1316_CR105","doi-asserted-by":"crossref","unstructured":"Kuijpers TW, de Vries AC, van Leeuwen EM, Ermens AT, de Pont S, Smith DE, Wamelink MM, Mensenkamp AR, Nelen MR, Lango Allen H, Pals ST (2022) Megalobastic anemia, infantile leukemia, and immunodeficiency caused by a novel homozygous mutation in the DHFR gene. Blood Adv 6:5829-34","DOI":"10.1182\/bloodadvances.2022007233"},{"key":"1316_CR106","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/nutrit\/nuab092","volume":"80","author":"KS Batista","year":"2022","unstructured":"Batista KS, Cintra VM, Lucena PA, Manh\u00e3es-de-Castro R, Toscano AE, Costa LP, Queiroz ME, de Andrade SM, Guzman-Quevedo O (2022) Aquino JdS: The role of vitamin B12 in viral infections: a comprehensive review of its relationship with the muscle\u2013gut\u2013brain axis and implications for SARS-CoV-2 infection. Nutr Rev 80:561\u2013578","journal-title":"Nutr Rev"},{"key":"1316_CR107","doi-asserted-by":"publisher","first-page":"001","DOI":"10.30574\/gscbps.2020.11.3.0155","volume":"11","author":"LMJ dos Santos","year":"2020","unstructured":"dos Santos LMJ (2020) Can vitamin B12 be an adjuvant to COVID-19 treatment? GSC Biol Pharm Sci 11:001\u2013005","journal-title":"GSC Biol Pharm Sci"},{"key":"1316_CR108","doi-asserted-by":"crossref","unstructured":"Babar Q, Ali A, Saeed A, Tahir MF: Novel treatment strategy against COVID-19 through anti-inflammatory, antioxidant and immunostimulatory properties of the b vitamin complex. In: B-Complex Vitamins-Sources, Intakes and Novel Applications. Intechopen. 2021.","DOI":"10.5772\/intechopen.100251"},{"key":"1316_CR109","doi-asserted-by":"crossref","unstructured":"Agarwal N, Khatri N, Singh P (2021) Pancytopenia in pregnant patients with COVID-19 infection and vitamin B12 deficiency: a case report study. JIDHealth 4:415-8","DOI":"10.47108\/jidhealth.Vol4.IssSpecial2.138"},{"key":"1316_CR110","doi-asserted-by":"publisher","first-page":"645013","DOI":"10.3389\/fimmu.2021.645013","volume":"12","author":"K-T Tang","year":"2021","unstructured":"Tang K-T, Hsu B-C, Chen D-Y (2021) Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review. Front Immunol 12:645013","journal-title":"Front Immunol"},{"key":"1316_CR111","doi-asserted-by":"crossref","unstructured":"Fattizzo B, Pasquale R, Bellani V, Barcellini W, Kulasekararaj AG (2021) Complement mediated hemolytic anemias in the COVID-19 era: case series and review of the literature. Front Immunol 12:791429.","DOI":"10.3389\/fimmu.2021.791429"},{"key":"1316_CR112","doi-asserted-by":"crossref","unstructured":"Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y (2021) The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 20:102792.","DOI":"10.1016\/j.autrev.2021.102792"},{"key":"1316_CR113","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s00277-022-04907-7","volume":"101","author":"HM Al-Kuraishy","year":"2022","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Kaushik A, Kujawska M (2022) Batiha GE-S: Hemolytic anemia in COVID-19. Ann Hematol 101:1887\u20131895","journal-title":"Ann Hematol"},{"key":"1316_CR114","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/ijlh.13978","volume":"45","author":"A Jafarzadeh","year":"2023","unstructured":"Jafarzadeh A, Jafarzadeh S, Pardehshenas M, Nemati M, Mortazavi SMJ (2023) Development and exacerbation of autoimmune hemolytic anemia following COVID-19 vaccination: a systematic review. Int J Lab Hematol 45:145\u2013155","journal-title":"Int J Lab Hematol"},{"key":"1316_CR115","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40121-022-00745-2","volume":"12","author":"TJ Gonz\u00e1lez-L\u00f3pez","year":"2023","unstructured":"Gonz\u00e1lez-L\u00f3pez TJ, B\u00e1rez A, Bernardo-Guti\u00e9rrez A, Bernat S, Canaro-Hirnyk M, Entrena-Ure\u00f1a L, Fern\u00e1ndez-Fuertes F, de GuineaCastro JM, Jim\u00e9nez-B\u00e1rcenas R, Pascual-Izquierdo C (2023) Recommendations on the management of patients with immune thrombocytopenia (ITP) in the context of SARS-CoV-2 infection and vaccination: consensus guidelines from a Spanish ITP expert group. Infect Dis Ther 12:303\u2013315","journal-title":"Infect Dis Ther"},{"key":"1316_CR116","doi-asserted-by":"publisher","first-page":"34","DOI":"10.14740\/jh954","volume":"11","author":"S Sridhara","year":"2022","unstructured":"Sridhara S, Nair R, Stanek M (2022) Severe aplastic anemia after receiving SARS-CoV-2 Moderna mRNA vaccination. J Hematol 11:34","journal-title":"J Hematol"},{"key":"1316_CR117","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1111\/ijlh.13653","volume":"44","author":"TM Murdych","year":"2022","unstructured":"Murdych TM (2022) A case of severe autoimmune hemolytic anemia after a receipt of a first dose of SARS-CoV-2 vaccine. Int J Lab Hematol 44:e10","journal-title":"Int J Lab Hematol"},{"key":"1316_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-021-02616-3","volume":"22","author":"B Osmanodja","year":"2021","unstructured":"Osmanodja B, Schreiber A, Schrezenmeier E, Seelow E (2021) First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine\u2013case report. BMC Nephrol 22:1\u20135","journal-title":"BMC Nephrol"},{"key":"1316_CR119","first-page":"1510","volume":"62","author":"S Okuno","year":"2021","unstructured":"Okuno S, Hashimoto K, Shimizu R, Takagi E, Kajiguchi T (2021) Development of autoimmune hemolytic anemia after BNT162b2 mRNA COVID-19 vaccination. Jpn J Clin Hematol 62:1510\u20131514","journal-title":"Jpn J Clin Hematol"},{"key":"1316_CR120","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s12185-021-03190-y","volume":"114","author":"SHB Waqar","year":"2021","unstructured":"Waqar SHB, Khan AA, Memon S (2021) Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine. Int J Hematol 114:626\u2013629","journal-title":"Int J Hematol"},{"key":"1316_CR121","doi-asserted-by":"publisher","first-page":"102782","DOI":"10.1016\/j.jaut.2021.102782","volume":"126","author":"S Tabata","year":"2022","unstructured":"Tabata S, Hosoi H, Murata S, Takeda S, Mushino T, Sonoki T (2022) Severe aplastic anemia after COVID-19 mRNA vaccination: causality or coincidence? J Autoimmun 126:102782","journal-title":"J Autoimmun"},{"key":"1316_CR122","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.annemergmed.2021.02.011","volume":"77","author":"JA Julian","year":"2021","unstructured":"Julian JA, Mathern DR, Fernando D (2021) Idiopathic thrombocytopenic purpura and the Moderna COVID-19 vaccine. Ann Emerg Med 77:654\u2013656","journal-title":"Ann Emerg Med"},{"key":"1316_CR123","first-page":"351","volume":"101","author":"HA Liebman","year":"2017","unstructured":"Liebman HA, Weitz IC (2017) Autoimmune hemolytic anemia. Med Clin 101:351\u2013359","journal-title":"Med Clin"},{"key":"1316_CR124","doi-asserted-by":"crossref","unstructured":"Hill A, Hill QA. Autoimmune hemolytic anemia. Hematology 2014, the American Society of Hematology Education Program Book. 2018:382-389.","DOI":"10.1182\/asheducation-2018.1.382"},{"key":"1316_CR125","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.3390\/jcm9123859","volume":"9","author":"W Barcellini","year":"2020","unstructured":"Barcellini W, Zaninoni A, Giannotta JA, Fattizzo B (2020) New insights in autoimmune hemolytic anemia: from pathogenesis to therapy. J Clin Med 9:3859","journal-title":"J Clin Med"},{"key":"1316_CR126","doi-asserted-by":"crossref","unstructured":"Mah\u00e9vas M, Moulis G, Andres E, Riviere E, Garzaro M, Crickx E, Guillotin V, Malphettes M, Galicier L, Noel N, Darnige L (2020) Clinical characteristics, management and outcome of COVID\u201019\u2010associated immune thrombocytopenia: a French multicentre series. Br J Haematol 190:e224-9","DOI":"10.1111\/bjh.17024"},{"key":"1316_CR127","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.1111\/bjh.17024","volume":"190","author":"M Mah\u00e9vas","year":"2020","unstructured":"Mah\u00e9vas M, Moulis G, Andres E, Riviere E, Garzaro M, Crickx E, Guillotin V, Malphettes M, Galicier L, Noel N (2020) Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. Br J Haematol 190:e224\u2013e229","journal-title":"Br J Haematol"},{"key":"1316_CR128","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/09537104.2022.2042237","volume":"33","author":"S-C Chou","year":"2022","unstructured":"Chou S-C, Chang Y-C, Liao C-K, Chen T-C, Sun K-J, Huang W-H, Wu Y-F (2022) New presentations and exacerbations of immune thrombocytopenia after coronavirus disease 2019 vaccinations: the Taiwan experience. Platelets 33:531\u2013535","journal-title":"Platelets"},{"key":"1316_CR129","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3390\/diagnostics12071555","volume":"12","author":"DS Mouliou","year":"2022","unstructured":"Mouliou DS, Dardiotis E (2022) Current evidence in SARS-CoV-2 mRNA vaccines and post-vaccination adverse reports: knowns and unknowns. Diagnostics 12:1555","journal-title":"Diagnostics"},{"key":"1316_CR130","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S1470-2045(20)30309-0","volume":"21","author":"J Tian","year":"2020","unstructured":"Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y (2020) Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol 21:893\u2013903","journal-title":"Lancet Oncol"},{"key":"1316_CR131","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3389\/fimmu.2016.00364","volume":"7","author":"MF Pascutti","year":"2016","unstructured":"Pascutti MF, Erkelens MN, Nolte MA (2016) Impact of viral infections on hematopoiesis: from beneficial to detrimental effects on bone marrow output. Front Immunol 7:364","journal-title":"Front Immunol"},{"key":"1316_CR132","doi-asserted-by":"publisher","first-page":"594556","DOI":"10.3389\/fimmu.2020.594556","volume":"11","author":"V Griggio","year":"2020","unstructured":"Griggio V, Perutelli F, Salvetti C, Boccellato E, Boccadoro M, Vitale C, Coscia M (2020) Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia. Front Immunol 11:594556","journal-title":"Front Immunol"},{"key":"1316_CR133","doi-asserted-by":"publisher","first-page":"738915","DOI":"10.3389\/fimmu.2021.738915","volume":"12","author":"A Allegra","year":"2021","unstructured":"Allegra A, Tonacci A, Musolino C, Pioggia G, Gangemi S (2021) Secondary immunodeficiency in hematological malignancies: focus on multiple myeloma and chronic lymphocytic leukemia. Front Immunol 12:738915","journal-title":"Front Immunol"},{"key":"1316_CR134","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000522436","volume":"145","author":"JC Mart\u00ednez","year":"2022","unstructured":"Mart\u00ednez JC, Sica RA, Stockerl-Goldstein K, Rubinstein SM (2022) COVID-19 in patients with hematologic malignancies: outcomes and options for treatments. Acta Haematologica 145:244\u2013256","journal-title":"Acta Haematologica"},{"key":"1316_CR135","doi-asserted-by":"crossref","unstructured":"Cutrona G, Tripodo C, Matis S, Recchia AG, Massucco C, Fabbi M, Colombo M, Emionite L, Sangaletti S, Gulino A, Reverberi D (2018) Microenvironmental regulation of the IL-23R\/IL-23 axis overrides chronic lymphocytic leukemia indolence. Sci Transl Med 10:eaal1571","DOI":"10.1126\/scitranslmed.aal1571"},{"key":"1316_CR136","doi-asserted-by":"crossref","unstructured":"Ye X, Xiao X, Li B, Zhu W, Li Y, Wu J, Huang X, Jin J, Chen D, Jin J, Huang J (2020) Low humoral immune response and ineffective clearance of SARS-Cov-2 in a COVID-19 patient with CLL during a 69-day follow-up. Front Oncol 10:1272","DOI":"10.3389\/fonc.2020.01272"},{"key":"1316_CR137","doi-asserted-by":"crossref","unstructured":"Largeaud L, Ribes A, Dubois-Galopin F, Memier V, Rolland Y, Gaudin C, Rousset D, Geeraerts T, Noel-Savina E, Rieu JB, Vergez F (2021) Major rise of a chronic lymphoid leukemia clone during the course of COVID-19. Int J Lab Hematol 43:e82\u20133","DOI":"10.1111\/ijlh.13383"},{"key":"1316_CR138","doi-asserted-by":"crossref","unstructured":"Allegra A, Pioggia G, Tonacci A, Musolino C, Gangemi S (2020) Cancer and SARS-CoV-2 infection: diagnostic and therapeutic challenges. Cancers 12:1581","DOI":"10.3390\/cancers12061581"},{"key":"1316_CR139","doi-asserted-by":"crossref","unstructured":"Li X, Shao M, Zeng X, Qian P, Huang H (2021) Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal Transduct Target Ther 6:367","DOI":"10.1038\/s41392-021-00764-4"},{"key":"1316_CR140","doi-asserted-by":"crossref","unstructured":"Dettorre GM, Patel M, Gennari A, Pentheroudakis G, Romano E, Cortellini A, Pinato DJ (2021) The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer. ESMO open 6:100123","DOI":"10.1016\/j.esmoop.2021.100123"},{"key":"1316_CR141","doi-asserted-by":"crossref","unstructured":"Ujjani CS, Gooley TA, Spurgeon SE, Stephens DM, Lai C, Broome CM, O'Brien SM, Zhu H, Laing KJ, Winter AM. Diminished humoral and cellular responses to SARS-CoV-2 Vaccines in patients with chronic lymphocytic leukemia. Blood Adv. 2022:bloodadvances. 2022009164.","DOI":"10.1182\/bloodadvances.2022009164"},{"key":"1316_CR142","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"JB Moore","year":"2020","unstructured":"Moore JB, June CH (2020) Cytokine release syndrome in severe COVID-19. Science 368:473\u2013474","journal-title":"Science"},{"key":"1316_CR143","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1038\/s41375-020-01030-2","volume":"34","author":"LE Roeker","year":"2020","unstructured":"Roeker LE, Knorr DA, Pessin MS, Ramanathan LV, Thompson MC, Leslie LA, Zelenetz AD, Mato AR (2020) Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia 34:3047\u20133049","journal-title":"Leukemia"},{"key":"1316_CR144","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s11033-021-06800-4","volume":"49","author":"M Heydarian","year":"2022","unstructured":"Heydarian M, Mohammadtaghizadeh M, Shojaei M, Babazadeh M, Abbasian S, Amrovani M (2022) The effect of COVID-19 derived cytokine storm on cancer cells progression: double-edged sword. Mol Biol Rep 49:605\u2013615","journal-title":"Mol Biol Rep"},{"key":"1316_CR145","doi-asserted-by":"publisher","first-page":"26","DOI":"10.52547\/rabms.7.1.26","volume":"7","author":"A Gandomi-Mohammadabadi","year":"2021","unstructured":"Gandomi-Mohammadabadi A, Divsalar F, Taram S, Kateb Z, Montazer F, Farbod Y (2021) COVID-19 in a patient with newly diagnosed chronic lymphocytic leukemia (CLL): a case report. J Res Appl Basic Med Sci 7:26\u201330","journal-title":"J Res Appl Basic Med Sci"},{"key":"1316_CR146","doi-asserted-by":"publisher","first-page":"e28391","DOI":"10.1002\/pbc.28391","volume":"67","author":"B Bernar","year":"2020","unstructured":"Bernar B, Kropshofer G, Crazzolara R, Kapelari K, Griesmacher A, M\u00fcller T, Scholl-B\u00fcrgi S (2020) SARS-CoV-2 infection in a 7-year-old girl with pancytopenia during acute lymphocytic leukemia maintenance therapy. Pediatr Blood Cancer 67:e28391","journal-title":"Pediatr Blood Cancer"},{"key":"1316_CR147","first-page":"144","volume":"126","author":"R Somasundaram","year":"2015","unstructured":"Somasundaram R, Prasad MA, Ungerb\u00e4ck J, Sigvardsson M (2015) Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia. Blood J Am Soc Hematol 126:144\u2013152","journal-title":"Blood J Am Soc Hematol"},{"key":"1316_CR148","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.exphem.2017.06.001","volume":"53","author":"T Sanda","year":"2017","unstructured":"Sanda T, Leong WZ (2017) TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia. Exp Hematol 53:7\u201315","journal-title":"Exp Hematol"},{"key":"1316_CR149","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/cancers10040110","volume":"10","author":"A Monta\u00f1o","year":"2018","unstructured":"Monta\u00f1o A, Forero-Castro M, Marchena-Mendoza D, Benito R, Hern\u00e1ndez-Rivas JM (2018) New challenges in targeting signaling pathways in acute lymphoblastic leukemia by NGS approaches: an update. Cancers 10:110","journal-title":"Cancers"},{"key":"1316_CR150","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.bulcan.2020.04.003","volume":"107","author":"A Baruchel","year":"2020","unstructured":"Baruchel A, Bertrand Y, Boissel N, Brethon B, Ducassou S, Gandemer V, Halfon-Domenech C, Leblanc T, Leverger G, Michel G (2020) COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against cancers and leukemias in children and adolescents (SFCE). Bulletin Du Cancer 107:629\u2013632","journal-title":"Bulletin Du Cancer"},{"key":"1316_CR151","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3892\/ol.2020.11583","volume":"20","author":"FL Huang","year":"2020","unstructured":"Huang FL, Liao EC, Li CL, Yen CY, Yu SJ (2020) Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: molecular pathways and disease treatments. Oncol Lett 20:448\u2013454","journal-title":"Oncol Lett"},{"key":"1316_CR152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-021-03174-w","volume":"19","author":"W Yan","year":"2021","unstructured":"Yan W, Song L, Wang H, Yang W, Hu L, Yang Y (2021) Extracellular vesicles carrying miRNA-181b-5p affects the malignant progression of acute lymphoblastic leukemia. J Transl Med 19:1\u20139","journal-title":"J Transl Med"},{"key":"1316_CR153","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s13337-021-00743-x","volume":"32","author":"M Iravani Saadi","year":"2021","unstructured":"Iravani Saadi M, Ramzi M, Hesami Z, Kheradmand N, Owjfard M, Nabi Abdolyousefi E, Karimi Z (2021) MiR-181a and-b expression in acute lymphoblastic leukemia and its correlation with acute graft-versus-host disease after hematopoietic stem cell transplantation, COVID-19 and torque teno viruses. Virusdisease 32:727\u2013736","journal-title":"Virusdisease"},{"key":"1316_CR154","doi-asserted-by":"publisher","first-page":"277","DOI":"10.15171\/apb.2018.032","volume":"8","author":"E Baghbani","year":"2018","unstructured":"Baghbani E, Khaze V, Sadreddini S, Mokhtarzadeh A, Mansoori B, Mohammadi A, Vatankhahan V, Toosi P, Baradaran B (2018) PTPN22 silencing in human acute T-cell leukemia cell line (Jurkat cell) and its effect on the expression of miR-181a and miR-181b. Adv Pharm Bull 8:277","journal-title":"Adv Pharm Bull"},{"key":"1316_CR155","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/v12060614","volume":"12","author":"ED Arisan","year":"2020","unstructured":"Arisan ED, Dart A, Grant GH, Arisan S, Cuhadaroglu S, Lange S, Uysal-Onganer P (2020) The prediction of miRNAs in SARS-CoV-2 genomes: hsa-miR databases identify 7 key miRs linked to host responses and virus pathogenicity-related KEGG pathways significant for comorbidities. Viruses 12:614","journal-title":"Viruses"},{"key":"1316_CR156","doi-asserted-by":"publisher","first-page":"108071","DOI":"10.1016\/j.intimp.2021.108071","volume":"100","author":"Z Amini-Farsani","year":"2021","unstructured":"Amini-Farsani Z, Yadollahi-Farsani M, Arab S, Forouzanfar F, Yadollahi M, Asgharzade S (2021) Prediction and analysis of microRNAs involved in COVID-19 inflammatory processes associated with the NF-kB and JAK\/STAT signaling pathways. Int immunopharmacol 100:108071","journal-title":"Int immunopharmacol"},{"key":"1316_CR157","doi-asserted-by":"publisher","first-page":"S277","DOI":"10.1016\/S2152-2650(21)01667-0","volume":"21","author":"M Badreldein","year":"2021","unstructured":"Badreldein M, Elsorady M, Alhadidi A, Gallab O, Eldabah N (2021) ALL-443: diagnostic and prognostic significance of miRNA-511 and miRNA-16 expression in adult B-Acute lymphoblastic leukemia patients. Clin Lymphoma Myeloma Leuk 21:S277","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1316_CR158","first-page":"22","volume":"6635925","author":"C-X Li","year":"2021","unstructured":"Li C-X, Chen J, Lv S-K, Li J-H, Li L-L, Hu X (2021) Whole-transcriptome RNA sequencing reveals significant differentially expressed mRNAs, miRNAs, and lncRNAs and related regulating biological pathways in the peripheral blood of COVID-19 patients. Mediators Inflamm 6635925:22","journal-title":"Mediators Inflamm"},{"key":"1316_CR159","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/carcin\/bgz183","volume":"41","author":"L Witten","year":"2020","unstructured":"Witten L, Slack FJ (2020) miR-155 as a novel clinical target for hematological malignancies. Carcinogenesis 41:2\u20137","journal-title":"Carcinogenesis"},{"key":"1316_CR160","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.pathol.2021.09.006","volume":"54","author":"RA-H Haroun","year":"2022","unstructured":"Haroun RA-H, Osman WH, Amin RE, Hassan AK, Abo-Shanab WS, Eessa AM (2022) Circulating plasma miR-155 is a potential biomarker for the detection of SARS-CoV-2 infection. Pathology 54:104\u2013110","journal-title":"Pathology"},{"key":"1316_CR161","doi-asserted-by":"publisher","first-page":"6260","DOI":"10.1158\/1078-0432.CCR-12-1708","volume":"18","author":"MT Di Martino","year":"2012","unstructured":"Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio MEG, Gull\u00e0 A, Conforti F, Morelli E (2012) Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo EvidenceAntitumor Activity of miR-34a in Multiple Myeloma. Clin Cancer Res 18:6260\u20136270","journal-title":"Clin Cancer Res"},{"key":"1316_CR162","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3390\/jpm12071030","volume":"12","author":"P Sagulkoo","year":"2022","unstructured":"Sagulkoo P, Chuntakaruk H, Rungrotmongkol T, Suratanee A, Plaimas K (2022) Multi-level biological network analysis and drug repurposing based on leukocyte transcriptomics in severe COVID-19: in silico systems biology to precision medicine. J Personal Med 12:1030","journal-title":"J Personal Med"},{"key":"1316_CR163","first-page":"1842","volume":"25","author":"A-F Liu","year":"2017","unstructured":"Liu A-F, Wang J-X, Li F-L, Chen Y-J (2017) Research progress on miR-125 family in malignant hematologic diseases-review. J Exp Hematol 25:1842\u20131846","journal-title":"J Exp Hematol"},{"key":"1316_CR164","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/bib\/bbab062","volume":"22","author":"S Zhang","year":"2021","unstructured":"Zhang S, Amahong K, Sun X, Lian X, Liu J, Sun H, Lou Y, Zhu F, Qiu Y (2021) The miRNA: a small but powerful RNA for COVID-19. Brief Bioinform 22:1137\u20131149","journal-title":"Brief Bioinform"},{"key":"1316_CR165","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/joim.12099","volume":"274","author":"M Haneklaus","year":"2013","unstructured":"Haneklaus M, Gerlic M, O\u2019Neill LA, Masters S (2013) miR-223: infection, inflammation and cancer. J Intern Med 274:215\u2013226","journal-title":"J Intern Med"},{"key":"1316_CR166","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1182\/blood.V126.23.2851.2851","volume":"126","author":"PP Leoncini","year":"2015","unstructured":"Leoncini PP, Bertaina A, Papaioannou D, Flotho C, Masetti R, Bresolin S, Menna G, Santoro N, Zecca M, Basso G (2015) MicroRNA-150 regulates STAT5b levels in juvenile myelomonocytic leukemia (JMML). Blood 126:2851","journal-title":"Blood"},{"key":"1316_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15476286.2021.2010959","volume":"19","author":"SM Akula","year":"2022","unstructured":"Akula SM, Bolin P, Cook PP (2022) Cellular miR-150-5p may have a crucial role to play in the biology of SARS-CoV-2 infection by regulating nsp10 gene. RNA Biol 19:1\u201311","journal-title":"RNA Biol"},{"key":"1316_CR168","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.3390\/ijms20112684","volume":"20","author":"JH Lee","year":"2019","unstructured":"Lee JH, Choi YS, Park JH, Kim H, Lee I, Won YB, Yun BH, Park JH, Seo SK, Lee BS (2019) miR-150-5p may contribute to pathogenesis of human leiomyoma via regulation of the Akt\/p27Kip1 pathway in vitro. Int J Mol Sci 20:2684","journal-title":"Int J Mol Sci"},{"key":"1316_CR169","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/ejhf.2322","volume":"23","author":"AA Derda","year":"2021","unstructured":"Derda AA, Garg A, B\u00e4r C, Thum T (2021) Reply to \u2018COVID-19 severity, miR-21 targets, and common human genetic variation.\u2019 Eur J Heart Fail 23:1987","journal-title":"Eur J Heart Fail"},{"key":"1316_CR170","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/carcin\/bgt044","volume":"34","author":"X Ma","year":"2013","unstructured":"Ma X, Choudhury SN, Hua X, Dai Z, Li Y (2013) Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway. Carcinogenesis 34:1216\u20131223","journal-title":"Carcinogenesis"},{"key":"1316_CR171","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-12-3325","volume":"19","author":"E Leone","year":"2013","unstructured":"Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gull\u00e0 A, Rossi M, Neri A, Giordano A, Munshi NC (2013) Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growthantitumor activity of mir-21 inhibitors in multiple myeloma. Clin Cancer Res 19:2096\u20132106","journal-title":"Clin Cancer Res"},{"key":"1316_CR172","doi-asserted-by":"publisher","first-page":"105195","DOI":"10.1016\/j.meegid.2021.105195","volume":"97","author":"N Askari","year":"2022","unstructured":"Askari N, Hadizadeh M, Rashidifar M (2022) A new insight into sex-specific non-coding RNAs and networks in response to SARS-CoV-2. Infect Genet Evol 97:105195","journal-title":"Infect Genet Evol"},{"key":"1316_CR173","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3109\/10428194.2012.704030","volume":"54","author":"S Sevcikova","year":"2013","unstructured":"Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R (2013) Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma 54:189\u2013191","journal-title":"Leuk Lymphoma"},{"key":"1316_CR174","doi-asserted-by":"publisher","first-page":"184","DOI":"10.5507\/bp.2014.037","volume":"159","author":"B Fiserovaa","year":"2015","unstructured":"Fiserovaa B, Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S (2015) The miR-29 family in hematological malignancies. Biomed Pap Med Fac Palacky Univ Olomouc 159:184\u2013191","journal-title":"Biomed Pap Med Fac Palacky Univ Olomouc"},{"key":"1316_CR175","doi-asserted-by":"publisher","first-page":"e35501","DOI":"10.1371\/journal.pone.0035501","volume":"7","author":"O Hershkovitz Rokah","year":"2012","unstructured":"Hershkovitz Rokah O, Granot G, Ovcharenko A, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Shpilberg O (2012) Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PloS one 7:e35501","journal-title":"PloS one"},{"key":"1316_CR176","doi-asserted-by":"publisher","first-page":"e1009759","DOI":"10.1371\/journal.ppat.1009759","volume":"17","author":"RJ Farr","year":"2021","unstructured":"Farr RJ, Rootes CL, Rowntree LC, Nguyen TH, Hensen L, Kedzierski L, Cheng AC, Kedzierska K, Au GG, Marsh GA (2021) Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection. PLoS Pathogens 17:e1009759","journal-title":"PLoS Pathogens"},{"key":"1316_CR177","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11899-018-0474-6","volume":"13","author":"T Zhou","year":"2018","unstructured":"Zhou T, Medeiros LJ, Hu S (2018) Chronic myeloid leukemia: beyond BCR-ABL1. Curr Hematol Malig Rep 13:435\u2013445","journal-title":"Curr Hematol Malig Rep"},{"key":"1316_CR178","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s11912-021-01169-w","volume":"24","author":"N Delgado","year":"2022","unstructured":"Delgado N, Torres A (2022) What do we currently know about chronic myeloid leukemia (CML) and COVID-19? Curr Oncol Rep 24:645\u2013650","journal-title":"Curr Oncol Rep"},{"key":"1316_CR179","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1111\/bcp.14353","volume":"86","author":"AE E\u015fkazan","year":"2020","unstructured":"E\u015fkazan AE (2020) Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic. Br J Clin Pharmacol 86:1790","journal-title":"Br J Clin Pharmacol"},{"key":"1316_CR180","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fonc.2019.00603","volume":"9","author":"V Garc\u00eda-Guti\u00e9rrez","year":"2019","unstructured":"Garc\u00eda-Guti\u00e9rrez V, Hern\u00e1ndez-Boluda JC (2019) Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol 9:603","journal-title":"Front Oncol"},{"key":"1316_CR181","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-019-02194-x","volume":"18","author":"R Alves","year":"2020","unstructured":"Alves R, McArdle SE, Vadakekolathu J, Gon\u00e7alves AC, Freitas-Tavares P, Pereira A, Almeida AM, Sarmento-Ribeiro AB, Rutella S (2020) Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-\u03b1. J Transl Med. 18:1\u201315","journal-title":"J Transl Med."},{"key":"1316_CR182","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3389\/fonc.2020.01428","volume":"10","author":"S Galimberti","year":"2020","unstructured":"Galimberti S, Petrini M, Barat\u00e8 C, Ricci F, Balducci S, Grassi S, Guerrini F, Ciabatti E, Mechelli S, Di Paolo A (2020) Tyrosine kinase inhibitors play an antiviral action in patients affected by chronic myeloid leukemia: a possible model supporting their use in the fight against SARS-CoV-2. Front Oncol 10:1428","journal-title":"Front Oncol"},{"key":"1316_CR183","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1080\/10428194.2021.1950709","volume":"62","author":"KB Pagnano","year":"2021","unstructured":"Pagnano KB, Peralta EH, Navarro JR, David Salas LDR, Delgado N, Moiraghi B, Toreli ACM, Perobelli LM, Fechio L, Quixada AT (2021) COVID-19 in chronic myeloid leukemia patients in Latin America. Leuk Lymphoma 62:3212\u20133218","journal-title":"Leuk Lymphoma"},{"key":"1316_CR184","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.bbamcr.2015.08.015","volume":"1863","author":"F Chiarini","year":"2016","unstructured":"Chiarini F, Lonetti A, Evangelisti C, Buontempo F, Orsini E, Evangelisti C, Cappellini A, Neri LM, McCubrey JA, Martelli AM (2016) Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: from biology to therapeutic targeting. Biochim Biophys Acta 1863:449\u2013463","journal-title":"Biochim Biophys Acta"},{"key":"1316_CR185","doi-asserted-by":"crossref","unstructured":"Grimwade D, Ivey A, Huntly BJ (2016) Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood 127:29-41","DOI":"10.1182\/blood-2015-07-604496"},{"key":"1316_CR186","doi-asserted-by":"crossref","unstructured":"Ferrara F, Zappasodi P, Roncoroni E, Borlenghi E, Rossi G (2020) Impact of COVID-19 on the treatment of acute myeloid leukemia. Leukemia 34:2254-6","DOI":"10.1038\/s41375-020-0925-7"},{"key":"1316_CR187","doi-asserted-by":"crossref","unstructured":"Zalpoor H, Bakhtiyari M, Akbari A, Aziziyan F, Shapourian H, Liaghat M, Zare-Badie Z, Yahyazadeh S, Tarhriz V, Ganjalikhani-Hakemi M (2022) Potential role of autophagy induced by FLT3-ITD and acid ceramidase in acute myeloid leukemia chemo-resistance: new insights. Cell Commun Signal 20:172","DOI":"10.1186\/s12964-022-00956-7"},{"key":"1316_CR188","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.leukres.2010.10.020","volume":"35","author":"G Deeb","year":"2011","unstructured":"Deeb G, Vaughan MM, McInnis I, Ford LA, Sait SN, Starostik P, Wetzler M, Mashtare T, Wang ES (2011) Hypoxia-inducible factor-1\u03b1 protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res 35:579\u2013584","journal-title":"Leuk Res"},{"key":"1316_CR189","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/cbin.11609","volume":"45","author":"S Sargazi","year":"2021","unstructured":"Sargazi S, Sheervalilou R, Rokni M, Shirvaliloo M, Shahraki O, Rezaei N (2021) The role of autophagy in controlling SARS-CoV-2 infection: An overview on virophagy-mediated molecular drug targets. Cell Biol Int 45:1599\u20131612","journal-title":"Cell Biol Int"},{"key":"1316_CR190","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1245\/s10434-020-08461-2","volume":"27","author":"DL Bartlett","year":"2020","unstructured":"Bartlett DL, Howe JR, Chang G, Crago A, Hogg M, Karakousis G, Levine E, Maker A, Mamounas E, McGuire K (2020) Management of cancer surgery cases during the COVID-19 pandemic: considerations. Ann Surg Oncol 27:1717\u20131720","journal-title":"Ann Surg Oncol"},{"key":"1316_CR191","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13027-022-00450-2","volume":"17","author":"H Zalpoor","year":"2022","unstructured":"Zalpoor H, Akbari A, Nayerain Jazi N, Liaghat M, Bakhtiyari M (2022) Possible role of autophagy induced by COVID-19 in cancer progression, chemo-resistance, and tumor recurrence. Infect Agents Cancer 17:38","journal-title":"Infect Agents Cancer"},{"key":"1316_CR192","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/ijlh.13387","volume":"43","author":"I Klimien\u0117","year":"2021","unstructured":"Klimien\u0117 I, Radzevi\u010dius M, Matuzevi\u010dien\u0117 R, Sinkevi\u010d-Belliot K, Ku\u010dinskien\u0117 ZA, Pe\u010deli\u016bnas V (2021) Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood. Int J Lab Hematol 43:403\u2013408","journal-title":"Int J Lab Hematol"},{"key":"1316_CR193","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1002\/ajh.26752","volume":"98","author":"MV Dhodapkar","year":"2023","unstructured":"Dhodapkar MV (2023) The immune system in multiple myeloma and precursor states: lessons and implications for immunotherapy and interception. Am J Hematol 98:S4\u2013S12","journal-title":"Am J Hematol"},{"key":"1316_CR194","doi-asserted-by":"publisher","first-page":"8045","DOI":"10.1200\/JCO.2022.40.16_suppl.8045","volume":"40","author":"T Akhlaghi","year":"2022","unstructured":"Akhlaghi T, Maclachlan K, Korde N, Mailankody S, Lesokhin AM, Hassoun H, Lu SX, Patel D, Shah UA, Tan C (2022) African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients. Am Soc Clin Oncol 40:8045\u20138045","journal-title":"Am Soc Clin Oncol"},{"key":"1316_CR195","doi-asserted-by":"crossref","unstructured":"Yarmohammadi H, Cunningham-Rundles C (2017) Idiopathic CD4 lymphocytopenia: Pathogenesis, etiologies, clinical presentations and treatment strategies. Ann Allergy Asthma Immunol 119:374-8","DOI":"10.1016\/j.anai.2017.07.021"},{"key":"1316_CR196","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.lungcan.2020.04.029","volume":"145","author":"M Sereno","year":"2020","unstructured":"Sereno M, Guti\u00e9rrez-Guti\u00e9rrez G, Sandoval C, Falagan S, Jimenez-Gordo AM, Merino M, L\u00f3pez-Menchaca R, Mart\u00ednez-Martin P, Roa S, Casado E (2020) A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: is immunosuppression a risk factor for SARS-COV2 infection? Lung Cancer 145:213\u2013215","journal-title":"Lung Cancer"},{"key":"1316_CR197","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-020-00934-x","volume":"13","author":"B Wang","year":"2020","unstructured":"Wang B, Van Oekelen O, Mouhieddine TH, Del Valle DM, Richter J, Cho HJ, Richard S, Chari A, Gnjatic S, Merad M (2020) A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematol Oncol 13:94","journal-title":"J Hematol Oncol"},{"key":"1316_CR198","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1158\/2643-3230.BCD-21-0166","volume":"2","author":"A Ribas","year":"2021","unstructured":"Ribas A, Dhodapkar MV, Campbell KM, Davies FE, Gore SD, Levy R, Greenberger LM (2021) How to provide the needed protection from COVID-19 to patients with hematologic malignancies. Blood Cancer Discov 2:562\u2013567","journal-title":"Blood Cancer Discov"},{"key":"1316_CR199","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1182\/blood.2020008109","volume":"137","author":"HC Hasselbalch","year":"2021","unstructured":"Hasselbalch HC, Elvers M, Schafer AI (2021) The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. Blood 137:2152\u20132160","journal-title":"Blood"},{"key":"1316_CR200","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2008-03-143602","volume":"112","author":"O Landgren","year":"2008","unstructured":"Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bj\u00f6rkholm M (2008) Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden. Blood 112:2199\u20132204","journal-title":"Blood"},{"key":"1316_CR201","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3324\/haematol.2019.235994","volume":"105","author":"A Veninga","year":"2020","unstructured":"Veninga A, De Simone I, Heemskerk JW, Ten Cate H, van der Meijden PE (2020) Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding. Haematologica 105:2020\u20132031","journal-title":"Haematologica"},{"key":"1316_CR202","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.jiph.2020.07.014","volume":"13","author":"H Ejaz","year":"2020","unstructured":"Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, Abosalif KO, Ahmed Z, Younas S (2020) COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health 13:1833\u20131839","journal-title":"J Infect Public Health"},{"key":"1316_CR203","doi-asserted-by":"crossref","unstructured":"Wolach O, Shacham Abulafia A (2021) Can Novel Insights into the Pathogenesis of Myeloproliferative Neoplasm-Related Thrombosis Inform Novel Treatment Approaches?. Hemato 2:305-28.","DOI":"10.3390\/hemato2020018"},{"key":"1316_CR204","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood.2019000568","volume":"134","author":"PG Murray","year":"2019","unstructured":"Murray PG, Young LS (2019) An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma. Blood 134:591\u2013596","journal-title":"Blood"},{"key":"1316_CR205","unstructured":"Pasin F, Calveri MM, Pizzarelli G, Calabrese A, Andreoli M, Bongiovanni I, Cattaneo C, Rignanese G (2020) Oncolytic effect of SARS-CoV2 in a patient with NK lymphoma. Acta Biomed 91:e2020047"},{"key":"1316_CR206","doi-asserted-by":"crossref","unstructured":"Yousif NG, Oton A, Chetterje K, Gupta M, Shankar M (2022) Complete remission of Hodgkin Lymphoma after a concurrent infection with COVID-19: systematic review and meta-analysis. Muthanna Med J 6:57-67","DOI":"10.52113\/1\/1\/2022-57-67"},{"key":"1316_CR207","doi-asserted-by":"crossref","unstructured":"Osman M, Faridi RM, Sligl W, Shabani-Rad MT, Dharmani-Khan P, Parker A, Kalra A, Tripathi MB, Storek J, Cohen Tervaert JW, Khan FM (2020) Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19. Blood Adv 4:5035-9","DOI":"10.1182\/bloodadvances.2020002650"},{"key":"1316_CR208","doi-asserted-by":"crossref","unstructured":"Huang I, Pranata R (2020) Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care 8:1-0","DOI":"10.1186\/s40560-020-00453-4"},{"key":"1316_CR209","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.3390\/ijms21176351","volume":"21","author":"C van Eeden","year":"2020","unstructured":"van Eeden C, Khan L, Osman MS, Cohen Tervaert JW (2020) Natural killer cell dysfunction and its role in COVID-19. Int J Mol Sci 21:6351","journal-title":"Int J Mol Sci"},{"key":"1316_CR210","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","volume":"115","author":"JA Sparano","year":"2010","unstructured":"Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH (2010) Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 115:3008\u20133016","journal-title":"Blood"},{"key":"1316_CR211","doi-asserted-by":"crossref","unstructured":"Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, Tabib Y, Cohen YC, Benyamini N, Beyar-Katz O, Neaman M (2021) Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood advances 5:3053\u201361","DOI":"10.1182\/bloodadvances.2021005094"},{"key":"1316_CR212","doi-asserted-by":"crossref","unstructured":"Terpos E, Gavriatopoulou M, Fotiou D, Giatra C, Asimakopoulos I, Dimou M, Sklirou AD, Ntanasis-Stathopoulos I, Darmani I, Briasoulis A, Kastritis E (2021) Poor neutralizing antibody responses in 132 patients with CLL, NHL and HL after vaccination against SARS-CoV-2: a prospective study. Cancers 13:4480","DOI":"10.3390\/cancers13174480"},{"key":"1316_CR213","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/bjh.18149","volume":"197","author":"J Riise","year":"2022","unstructured":"Riise J, Meyer S, Blaas I, Chopra A, Tran TT, Delic-Sarac M, Hestdalen ML, Brodin E, Rustad EH, Dai KZ (2022) Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. Br J Haematol 197:697\u2013708","journal-title":"Br J Haematol"},{"key":"1316_CR214","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","volume":"7","author":"F Passamonti","year":"2020","unstructured":"Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, Angelucci E, Krampera M, Cairoli R, Della Porta MG (2020) Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 7:e737\u2013e745","journal-title":"Lancet Haematol"},{"key":"1316_CR215","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/jmv.26404","volume":"93","author":"TN Yigenoglu","year":"2021","unstructured":"Yigenoglu TN, Ata N, Altuntas F, Basc\u0131 S, Dal MS, Korkmaz S, Namdaroglu S, Basturk A, Hac\u0131bekiroglu T, Dogu MH (2021) The outcome of COVID-19 in patients with hematological malignancy. J Med Virol 93:1099\u20131104","journal-title":"J Med Virol"},{"key":"1316_CR216","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(20)30310-7","volume":"21","author":"K Yang","year":"2020","unstructured":"Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, Lu H, Liu J, Yang J, Dong Y (2020) Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 21:904\u2013913","journal-title":"Lancet Oncol"},{"key":"1316_CR217","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/ejh.13493","volume":"105","author":"JM Sanchez-Pina","year":"2020","unstructured":"Sanchez-Pina JM, Rodr\u00edguez Rodriguez M, Castro Quismondo N, Gil Manso R, Colmenares R, Gil Alos D, Paciello ML, Zafra D, Garcia-Sanchez C, Villegas C (2020) Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. Eur J Haematol 105:597\u2013607","journal-title":"Eur J Haematol"},{"key":"1316_CR218","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s10238-020-00679-4","volume":"21","author":"G Bergamaschi","year":"2021","unstructured":"Bergamaschi G, de BorrelliAndreis F, Aronico N, Lenti MV, Barteselli C, Merli S, Pellegrino I, Coppola L, Cremonte EM, Croce G (2021) Anemia in patients with Covid-19: pathogenesis and clinical significance. Clin Exp Med 21:239\u2013246","journal-title":"Clin Exp Med"},{"key":"1316_CR219","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/jmv.26444","volume":"93","author":"Z Tao","year":"2021","unstructured":"Tao Z, Xu J, Chen W, Yang Z, Xu X, Liu L, Chen R, Xie J, Liu M, Wu J (2021) Anemia is associated with severe illness in COVID-19: a retrospective cohort study. J Med Virol 93:1478\u20131488","journal-title":"J Med Virol"},{"key":"1316_CR220","doi-asserted-by":"publisher","first-page":"e0262784","DOI":"10.1371\/journal.pone.0262784","volume":"17","author":"A Candoni","year":"2022","unstructured":"Candoni A, Petruzzellis G, Sperotto A, Andreotti V, Giavarra M, Corvaja C, Minisini A, Comuzzi C, Tascini C, Fanin R (2022) Detection of SARS-CoV-2 infection prevalence in 860 cancer patients with a combined screening procedure including triage, molecular nasopharyngeal swabs and rapid serological test. A report from the first epidemic wave. PloS one 17:e0262784","journal-title":"PloS one"},{"key":"1316_CR221","doi-asserted-by":"crossref","unstructured":"Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, Tabib Y, Cohen YC, Benyamini N, Beyar-Katz O, Neaman M (2021) Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv 5:3053-61","DOI":"10.1182\/bloodadvances.2021005094"},{"key":"1316_CR222","doi-asserted-by":"crossref","unstructured":"Langerbeins P, Hallek M (2022) COVID-19 in patients with hematologic malignancy. Blood 140:236-52","DOI":"10.1182\/blood.2021012251"},{"key":"1316_CR223","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403\u2013416","journal-title":"N Engl J Med"},{"key":"1316_CR224","doi-asserted-by":"crossref","unstructured":"Racine \u00c9, Gilca V, Amini R, Tunis M, Ismail S, Sauvageau C (2020) A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18\u201349 year old patients. Vaccine 38:6205-14","DOI":"10.1016\/j.vaccine.2020.07.049"},{"key":"1316_CR225","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/ajt.14683","volume":"18","author":"KL Dooling","year":"2018","unstructured":"Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R (2018) Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. Am J Transpl 18:756\u2013762","journal-title":"Am J Transpl"},{"key":"1316_CR226","doi-asserted-by":"crossref","unstructured":"Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, Sohn SK, Mac\u00edas GR, Chiou TJ, Quiel D, Aoun M (2019) Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis 19:988-1000","DOI":"10.1016\/S1473-3099(19)30163-X"},{"key":"1316_CR227","doi-asserted-by":"crossref","unstructured":"Natarajan K, Prasad N, Dascomb K, Irving SA, Yang DH, Gaglani M, Klein NP, DeSilva MB, Ong TC, Grannis SJ, Stenehjem E (2022) Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad. 26. COV2. S (Janssen [Johnson & Johnson]) vaccine dose against COVID-19\u2013associated emergency department and urgent care encounters and hospitalizations among adults\u2014VISION Network, 10 states, December 2021\u2013March 2022. Morbidity and Mortality Weekly Report. 71:495","DOI":"10.15585\/mmwr.mm7113e2"},{"key":"1316_CR228","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1001\/jama.2021.2927","volume":"325","author":"EH Livingston","year":"2021","unstructured":"Livingston EH, Malani PN, Creech CB (2021) The Johnson & Johnson vaccine for COVID-19. Jama 325:1575\u20131575","journal-title":"Jama"},{"key":"1316_CR229","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/leu.2010.278","volume":"25","author":"J Rossignol","year":"2011","unstructured":"Rossignol J, Michallet A, Oberic L, Picard M, Garon A, Willekens C, Dulery R, Leleu X, Cazin B, Ysebaert L (2011) Rituximab\u2013cyclophosphamide\u2013dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia 25:473\u2013478","journal-title":"Leukemia"},{"key":"1316_CR230","doi-asserted-by":"publisher","first-page":"100099","DOI":"10.1016\/j.jtauto.2021.100099","volume":"4","author":"M Scheinberg","year":"2021","unstructured":"Scheinberg M, Machado LA, Castro LGM, Ferreira SB, Michalany N (2021) Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. J Transl Autoimmun 4:100099","journal-title":"J Transl Autoimmun"},{"issue":"4","key":"1316_CR231","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/jcm7040062","volume":"7","author":"R Campbell","year":"2018","unstructured":"Campbell R, Chong G, Hawkes EA (2018) Novel indications for Bruton\u2019s tyrosine kinase inhibitors, beyond hematological malignancies. J Clin Med 7(4):62","journal-title":"J Clin Med"},{"key":"1316_CR232","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1517\/14740338.2015.1088827","volume":"14","author":"PT McGann","year":"2015","unstructured":"McGann PT, Ware RE (2015) Hydroxyurea therapy for sickle cell anemia. Exp Opin Drug Saf 14:1749\u20131758","journal-title":"Exp Opin Drug Saf"},{"key":"1316_CR233","doi-asserted-by":"publisher","first-page":"JC17","DOI":"10.7326\/ACPJ202102160-017","volume":"174","author":"R Zhang","year":"2021","unstructured":"Zhang R, Mylonakis E (2021) In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon \u03b2-1a differed from standard care for in-hospital mortality. Ann Intern Med 174:JC17","journal-title":"Ann Intern Med"},{"key":"1316_CR234","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"RW Hendriks","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP (2014) Targeting Bruton\u2019s tyrosine kinase in B cell malignancies. Nat Rev Cancer 14:219\u2013232","journal-title":"Nat Rev Cancer"},{"key":"1316_CR235","doi-asserted-by":"publisher","first-page":"e268","DOI":"10.1038\/bcj.2014.84","volume":"4","author":"A Pardanani","year":"2014","unstructured":"Pardanani A, Tefferi A (2014) Definition and management of ruxolitinib treatment failure in myelofibrosis. Blood Cancer J 4:e268\u2013e268","journal-title":"Blood Cancer J"},{"key":"1316_CR236","doi-asserted-by":"publisher","first-page":"212574","DOI":"10.7573\/dic.212574","volume":"8","author":"LM Ju\u00e1rez-Salcedo","year":"2019","unstructured":"Ju\u00e1rez-Salcedo LM, Desai V, Dalia S (2019) Venetoclax: evidence to date and clinical potential. Drugs Context 8:212574","journal-title":"Drugs Context"},{"key":"1316_CR237","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1177\/0091270005277075","volume":"45","author":"CM Ng","year":"2005","unstructured":"Ng CM, Bruno R, Combs D, Davies B (2005) Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 45:792\u2013801","journal-title":"J Clin Pharmacol"},{"key":"1316_CR238","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.3390\/curroncol29060315","volume":"29","author":"C Owen","year":"2022","unstructured":"Owen C, Robinson S, Christofides A, Sehn LH (2022) A Canadian perspective: Monoclonal antibodies for pre-and post-exposure protection from COVID-19 in vulnerable patients with hematological malignancies. Curr Oncol 29:3940\u20133949","journal-title":"Curr Oncol"},{"key":"1316_CR239","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/v14030650","volume":"14","author":"G Cicchitto","year":"2022","unstructured":"Cicchitto G, Cardillo L, de Martinis C, Sabatini P, Marchitiello R, Abate G, Rovetti A, Cavallera A, Apuzzo C, Ferrigno F (2022) Effects of casirivimab\/imdevimab monoclonal antibody treatment among vaccinated patients infected by SARS-CoV-2 delta variant. Viruses 14:650","journal-title":"Viruses"},{"key":"1316_CR240","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/jcph.1795","volume":"61","author":"C Xu","year":"2021","unstructured":"Xu C, Rafique A, Potocky T, Paccaly A, Nolain P, Lu Q, Iglesias-Rodriguez M, St John G, Nivens MC, Kanamaluru V (2021) Differential binding of Sarilumab and Tocilizumab to IL-6R\u03b1 and effects of receptor occupancy on clinical parameters. J Clin Pharmacol 61:714\u2013724","journal-title":"J Clin Pharmacol"},{"key":"1316_CR241","doi-asserted-by":"publisher","first-page":"103938","DOI":"10.1016\/j.msard.2022.103938","volume":"64","author":"DS Mouliou","year":"2022","unstructured":"Mouliou DS, Dardiotis E (2022) Temelimab for MS and SARS-CoV-2: could it be a double-edged blessing? Mult Scler Relat Disord 64:103938","journal-title":"Mult Scler Relat Disord"},{"key":"1316_CR242","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3390\/biomedicines11030936","volume":"11","author":"E Stricker","year":"2023","unstructured":"Stricker E, Peckham-Gregory EC, Scheurer ME (2023) HERVs and cancer\u2014A comprehensive review of the relationship of human endogenous retroviruses and human cancers. Biomedicines 11:936","journal-title":"Biomedicines"},{"key":"1316_CR243","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41408-021-00478-4","volume":"11","author":"J Mikhael","year":"2021","unstructured":"Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, Pour L, Spicka I, Vij R, Zonder J (2021) A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood cancer journal. 11:89","journal-title":"Blood cancer journal."},{"key":"1316_CR244","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1056\/NEJMoa1103975","volume":"365","author":"P Scheinberg","year":"2011","unstructured":"Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, Young NS (2011) Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 365:430\u2013438","journal-title":"N Engl J Med"},{"key":"1316_CR245","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/s41409-019-0465-9","volume":"54","author":"JR Passweg","year":"2019","unstructured":"Passweg JR, Baldomero H, Basak GW, Chabannon C, Corbacioglu S, Duarte R, Kuball J, Lankester A, Montoto S, de Latour RP (2019) The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transpl 54:1575\u20131585","journal-title":"Bone Marrow Transpl"},{"key":"1316_CR246","doi-asserted-by":"publisher","first-page":"102956","DOI":"10.1016\/j.transci.2020.102956","volume":"60","author":"R Shankar","year":"2021","unstructured":"Shankar R, Radhakrishnan N, Dua S, Arora S, Rana M, Sahu DK, Rai S, Gupta DK (2021) Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia. Transfus Apher Sci 60:102956","journal-title":"Transfus Apher Sci"},{"key":"1316_CR247","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/j.1442-200x.2001.01373.x","volume":"43","author":"K Hashino","year":"2001","unstructured":"Hashino K, Ishii M, Iemura M, Akagi T, Kato H (2001) Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 43:211\u2013217","journal-title":"Pediatr Int"},{"key":"1316_CR248","doi-asserted-by":"publisher","first-page":"eabj7211","DOI":"10.1126\/scitranslmed.abj7211","volume":"13","author":"PA Swanson","year":"2021","unstructured":"Swanson PA, Padilla M, Hoyland W, McGlinchey K, Fields PA, Bibi S, Faust SN, McDermott AB, Lambe T, Pollard AJ (2021) AZD1222\/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein\u2013specific TH1 response with a diverse TCR repertoire. Sci Transl Med 13:eabj7211","journal-title":"Sci Transl Med"},{"key":"1316_CR249","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","volume":"27","author":"KJ Ewer","year":"2021","unstructured":"Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, Flaxman A, Wright D, Bellamy D, Bittaye M (2021) T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial. Nat Med 27:270\u2013278","journal-title":"Nat Med"},{"key":"1316_CR250","doi-asserted-by":"crossref","unstructured":"Welniak LA, Blazar BR, Murphy WJ (2007) Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 25:139-70","DOI":"10.1146\/annurev.immunol.25.022106.141606"},{"key":"1316_CR251","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ccell.2022.05.007","volume":"40","author":"R Stuver","year":"2022","unstructured":"Stuver R, Shah GL, Korde NS, Roeker LE, Mato AR, Batlevi CL, Chung DJ, Doddi S, Falchi L, Gyurkocza B (2022) Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell 40:590\u2013591","journal-title":"Cancer Cell"},{"key":"1316_CR252","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1182\/bloodadvances.2022009475","volume":"7","author":"A Chang","year":"2023","unstructured":"Chang A, Koff JL, Lai L, Orellana-Noia VM, Surati M, Leal AM, Ellis ML, Wali B, Moreno A, Linderman SL (2023) Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B cell malignancies. Blood Adv 7:2459\u20132462","journal-title":"Blood Adv"},{"key":"1316_CR253","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41409-022-01894-1","volume":"58","author":"A Otiniano","year":"2023","unstructured":"Otiniano A, van de Wyngaert Z, Brissot E, Dulery R, Gozlan J, Daguenel A, Abi Aad Y, Ricard L, Stocker N, Banet A (2023) Tixagevimab\/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases. Bone Marrow Transpl 58:340\u2013342","journal-title":"Bone Marrow Transpl"},{"key":"1316_CR254","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1182\/blood.2022017071","volume":"140","author":"L Scarf\u00f2","year":"2022","unstructured":"Scarf\u00f2 L, Herishanu Y (2022) CLL and COVID-19: light at the end of the tunnel? Blood 140:407\u2013409","journal-title":"Blood"},{"key":"1316_CR255","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/16078454.2022.2082725","volume":"27","author":"F Djebbari","year":"2022","unstructured":"Djebbari F, Rampotas A, Vallance G, Panitsas F, Basker N, Sangha G, Salhan B, Karim F, Firas A-K, Gudger A (2022) Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study. Hematology 27:691\u2013699","journal-title":"Hematology"},{"key":"1316_CR256","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"Group RC","year":"2021","unstructured":"Group RC (2021) Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 384:693\u2013704","journal-title":"N Engl J Med"},{"key":"1316_CR257","doi-asserted-by":"publisher","first-page":"e00200","DOI":"10.1128\/AAC.00200-21","volume":"65","author":"MA Martinez","year":"2021","unstructured":"Martinez MA (2021) Plitidepsin: a repurposed drug for the treatment of COVID-19. Antimicrob Agents Chemother 65:e00200\u201300221","journal-title":"Antimicrob Agents Chemother"},{"key":"1316_CR258","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.7150\/ijbs.72544","volume":"18","author":"W He","year":"2022","unstructured":"He W, Gao Y, Zhou J, Shi Y, Xia D, Shen H-M (2022) Friend or Foe? Implication of the autophagy-lysosome pathway in SARS-CoV-2 infection and COVID-19. Int J Biol Sci 18:4690","journal-title":"Int J Biol Sci"},{"key":"1316_CR259","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/jpm11070668","volume":"11","author":"M Papapanou","year":"2021","unstructured":"Papapanou M, Papoutsi E, Giannakas T, Katsaounou P (2021) Plitidepsin: Mechanisms and clinical profile of a promising antiviral agent against COVID-19. J Personal Med 11:668","journal-title":"J Personal Med"},{"key":"1316_CR260","doi-asserted-by":"publisher","first-page":"712603","DOI":"10.3389\/fped.2021.712603","volume":"9","author":"GB Dell'Isola","year":"2021","unstructured":"Dell\u2019Isola GB, Felicioni M, Ferraro L, Capolsini I, Cerri C, Gurdo G, Mastrodicasa E, Massei MS, Perruccio K, Brogna M (2021) Case report: remdesivir and convalescent plasma in a newly acute B lymphoblastic leukemia diagnosis with concomitant sars-CoV-2 infection. Front Pediatr 9:712603","journal-title":"Front Pediatr"},{"key":"1316_CR261","doi-asserted-by":"crossref","unstructured":"Guo W, Zheng Y, Feng S (2023) Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes. Frontiers in Cellular and Infection Microbiology 13: 1207225","DOI":"10.3389\/fcimb.2023.1207225"},{"key":"1316_CR262","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.annonc.2021.07.015","volume":"32","author":"F Pommeret","year":"2021","unstructured":"Pommeret F, Colomba J, Bigenwald C, Laparra A, Bockel S, Bayle A, Michot J-M, Hueso T, Albiges L, Tiberghien P (2021) Bamlanivimab+ etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies. Ann Oncol 32:1445\u20131447","journal-title":"Ann Oncol"},{"key":"1316_CR263","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/22221751.2022.2026739","volume":"11","author":"B Mao","year":"2022","unstructured":"Mao B, Le-Trilling VTK, Wang K, Mennerich D, Hu J, Zhao Z, Zheng J, Deng Y, Katschinski B, Xu S (2022) Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro. Emerg Microbes Infect 11:483\u2013497","journal-title":"Emerg Microbes Infect"},{"key":"1316_CR264","doi-asserted-by":"publisher","first-page":"e15919","DOI":"10.15252\/emmm.202215919","volume":"14","author":"M Chan","year":"2022","unstructured":"Chan M, Holland EC, Gujral TS (2022) Olverembatinib inhibits SARS-CoV-2-Omicron variant-mediated cytokine release in human peripheral blood mononuclear cells. EMBO Mol Med 14:e15919","journal-title":"EMBO Mol Med"},{"key":"1316_CR265","doi-asserted-by":"publisher","first-page":"103297","DOI":"10.1016\/j.sjbs.2022.103297","volume":"29","author":"AB Gurung","year":"2022","unstructured":"Gurung AB, Ali MA, Elshikh MS, Aref I, Amina M, Lee J (2022) An in silico approach unveils the potential of antiviral compounds in preclinical and clinical trials as SARS-CoV-2 omicron inhibitors. Saudi J Biol Sci 29:103297","journal-title":"Saudi J Biol Sci"},{"key":"1316_CR266","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.scib.2022.02.002","volume":"67","author":"X Lin","year":"2022","unstructured":"Lin X, Ke X, Jian X, Xia L, Yang Y, Zhang T, Xiong H, Zhao B, Liu W, Chen Q (2022) Azacytidine targeting SARS-CoV-2 viral RNA as a potential treatment for COVID-19. Sci Bullet 67:1022","journal-title":"Sci Bullet"},{"key":"1316_CR267","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1021\/acsinfecdis.1c00278","volume":"7","author":"ME Carter-Timofte","year":"2021","unstructured":"Carter-Timofte ME, Arulanandam R, Kurmasheva N, Fu K, Laroche G, Taha Z, van Der Horst D, Cassin L, van der Sluis RM, Palermo E (2021) Antiviral potential of the antimicrobial drug atovaquone against SARS-CoV-2 and emerging variants of concern. ACS Infect Dis 7:3034\u20133051","journal-title":"ACS Infect Dis"},{"key":"1316_CR268","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01219-7","volume":"15","author":"H Parry","year":"2022","unstructured":"Parry H, McIlroy G, Bruton R, Damery S, Tyson G, Logan N, Davis C, Willett B, Zuo J, Ali M (2022) Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia. J Hematol Oncol 15:1\u201312","journal-title":"J Hematol Oncol"},{"key":"1316_CR269","doi-asserted-by":"publisher","first-page":"7641","DOI":"10.3390\/ijms22147641","volume":"22","author":"C Brullo","year":"2021","unstructured":"Brullo C, Villa C, Tasso B, Russo E, Spallarossa A (2021) Btk inhibitors: a medicinal chemistry and drug delivery perspective. Int J Mol Sci 22:7641","journal-title":"Int J Mol Sci"},{"key":"1316_CR270","doi-asserted-by":"crossref","unstructured":"Henriquez S, Zerbit J, Bruel T, Ouedrani A, Planas D, Deschamps P, Staropoli I, Hadjadj J, Varet B, Suarez F, Ermark N (2021) Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients. MedRxiv","DOI":"10.1101\/2021.08.08.21261769"},{"key":"1316_CR271","doi-asserted-by":"crossref","unstructured":"Nooka AK, Shanmugasundaram U, Cheedarla N, Verkerke H, Edara VV, Valanparambil R, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Azeem M (2022) Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma. J Clin Oncol 40:3057","DOI":"10.1200\/JCO.21.02257"},{"key":"1316_CR272","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1182\/blood.2022016815","volume":"140","author":"L Blixt","year":"2022","unstructured":"Blixt L, Gao Y, Wullimann D, Mur\u00e9n Ingelman-Sundberg H, Muschiol S, Healy K, Bogdanovic G, Pin E, Nilsson P, Kjellander C (2022) Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination. Blood 140:2403\u20132407","journal-title":"Blood"},{"key":"1316_CR273","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1002\/mco2.172","volume":"3","author":"A Xu","year":"2022","unstructured":"Xu A, Hong B, Lou F, Wang S, Li W, Shafqat A, An X, Zhao Y, Song L, Tong Y (2022) Sub-lineages of the SARS-CoV-2 Omicron variants: characteristics and prevention. MedComm 3:e172","journal-title":"MedComm"},{"key":"1316_CR274","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1182\/blood.2022016087","volume":"139","author":"L Bellusci","year":"2022","unstructured":"Bellusci L, Grubbs G, Srivastava P, Nemeth MJ, Griffiths EA, Golding H, Khurana S (2022) Neutralization of SARS-CoV-2 Omicron after vaccination of patients with myelodysplastic syndromes or acute myeloid leukemia. Blood 139:2842\u20132846","journal-title":"Blood"},{"key":"1316_CR275","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1182\/blood.2021013714","volume":"139","author":"S Henriquez","year":"2022","unstructured":"Henriquez S, Zerbit J, Bruel T, Ouedrani A, Planas D, Deschamps P, Staropoli I, Hadjadj J, Varet B, Ermak N (2022) Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma. Blood 139:942\u2013946","journal-title":"Blood"},{"key":"1316_CR276","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.ccell.2021.09.001","volume":"39","author":"LM Greenberger","year":"2021","unstructured":"Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL (2021) Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies. Cancer Cell 39:1297\u20131299","journal-title":"Cancer Cell"},{"key":"1316_CR277","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s43018-022-00364-3","volume":"3","author":"SH Lim","year":"2022","unstructured":"Lim SH, Stuart B, Joseph-Pietras D, Johnson M, Campbell N, Kelly A, Jeffrey D, Turaj AH, Rolfvondenbaumen K, Galloway C (2022) Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nat Cancer 3:552\u2013564","journal-title":"Nat Cancer"},{"key":"1316_CR278","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/ana.26309","volume":"91","author":"B Kornek","year":"2022","unstructured":"Kornek B, Leutmezer F, Rommer PS, Koblischke M, Schneider L, Haslacher H, Thalhammer R, Zimprich F, Zulehner G, Bsteh G (2022) B cell depletion and SARS-CoV-2 vaccine responses in neuroimmunologic patients. Ann Neurol 91:342\u2013352","journal-title":"Ann Neurol"},{"key":"1316_CR279","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.vaccine.2023.01.064","volume":"41","author":"SB Gressens","year":"2023","unstructured":"Gressens SB, Wiedemann A, D\u00e9chenaud M, Dupuis J, Gallien S, Melica G, Haioun C, Lemonnier F, Levy Y (2023) Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies. Vaccine 41:1550\u20131553","journal-title":"Vaccine"},{"key":"1316_CR280","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.1182\/blood-2022-163521","volume":"140","author":"E Terpos","year":"2022","unstructured":"Terpos E, Rosati M, Bear J, Burns R, Ntanasis-Stathopoulos I, Devasundaram S, Gavriatopoulou M, Kastritis E, Dimopoulos M-A, Pavlakis GN (2022) Antibody Response to COVID-19 mRNA vaccine in patients with multiple myeloma and waldenstrom\u2019s macroglobulinemia after primary immunization and booster: reactivity to the Sars-Cov-2 WT virus, delta and omicron variants. Blood. 140:4334\u20134335","journal-title":"Blood."},{"key":"1316_CR281","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3389\/fmolb.2022.1080964","volume":"9","author":"AM Fredericks","year":"2022","unstructured":"Fredericks AM, East KW, Shi Y, Liu J, Maschietto F, Ayala A, Cioffi WG, Cohen M, Fairbrother WG, Lefort CT (2022) Identification and mechanistic basis of non-ACE2 blocking neutralizing antibodies from COVID-19 patients with deep RNA sequencing and molecular dynamics simulations. Front Mol Biosci 9:1362","journal-title":"Front Mol Biosci"},{"key":"1316_CR282","doi-asserted-by":"publisher","first-page":"eabp9312","DOI":"10.1126\/sciimmunol.abp9312","volume":"7","author":"W Du","year":"2022","unstructured":"Du W, Hurdiss DL, Drabek D, Mykytyn AZ, Kaiser FK, Gonz\u00e1lez-Hern\u00e1ndez M, Mu\u00f1oz-Santos D, Lamers MM, van Haperen R, Li W (2022) An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern. Sci Immunol 7:eabp9312","journal-title":"Sci Immunol"},{"key":"1316_CR283","first-page":"96","volume":"4","author":"CM Denkinger","year":"2023","unstructured":"Denkinger CM, Janssen M, Schaekel U, Gall J, Leo A, Stelmach P, Weber SF, Krisam J, Baumann L, Stermann J (2023) Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer 4:96\u2013107","journal-title":"Nat Cancer"},{"key":"1316_CR284","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1182\/blood.2022016175","volume":"140","author":"D Atanackovic","year":"2022","unstructured":"Atanackovic D, Luetkens T, Omili D, Iraguha T, Lutfi F, Hardy NM, Fan X, Avila SV, Saharia KK, Husson JS (2022) Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell\u2013depleted lymphoma after CART therapy. Blood 140:152\u2013156","journal-title":"Blood"},{"key":"1316_CR285","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.3390\/v14112377","volume":"14","author":"J Zerbit","year":"2022","unstructured":"Zerbit J, Detroit M, Meyer A, Decroocq J, Deau-Fischer B, Deschamps P, Birsen R, Mondesir J, Franchi P, Miekoutima E (2022) Patients with hematological malignancies treated with T-cell or B-cell immunotherapy remain at high risk of severe forms of COVID-19 in the omicron era. Viruses 14:2377","journal-title":"Viruses"},{"key":"1316_CR286","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1053\/j.seminhematol.2022.11.001","volume":"59","author":"S Haggenburg","year":"2022","unstructured":"Haggenburg S, Hofsink Q, Rutten CE, Nijhof IS, Hazenberg MD, Goorhuis A (2022) SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies. Semin Hematol 59:192\u2013197","journal-title":"Semin Hematol"},{"key":"1316_CR287","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood.2021012249","volume":"140","author":"SR Conway","year":"2022","unstructured":"Conway SR, Keller MD, Bollard CM (2022) Cellular therapies for the treatment and prevention of SARS-CoV-2 infection. Blood 140:208\u2013221","journal-title":"Blood"},{"key":"1316_CR288","doi-asserted-by":"publisher","first-page":"e28158","DOI":"10.1002\/jmv.28158","volume":"95","author":"Z Li","year":"2023","unstructured":"Li Z, Yong H, Wang W, Gao Y, Wang P, Chen X, Lu J, Zheng J, Bai J (2023) GSK3326595 is a promising drug to prevent SARS-CoV-2 Omicron and other variants infection by inhibiting ACE2-R671 di-methylation. J Med Virol 95:e28158","journal-title":"J Med Virol"},{"key":"1316_CR289","first-page":"81","volume":"4","author":"A Keppler-Hafkemeyer","year":"2023","unstructured":"Keppler-Hafkemeyer A, Greil C, Wratil PR, Shoumariyeh K, Stern M, Hafkemeyer A, Ashok D, Hollaus A, Lupoli G, Priller A (2023) Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma. Nat Cancer 4:81\u201395","journal-title":"Nat Cancer"},{"key":"1316_CR290","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1111\/ajt.16927","volume":"22","author":"K Martits-Chalangari","year":"2022","unstructured":"Martits-Chalangari K, Spak CW, Askar M, Killian A, Fisher TL, Atillasoy E, Marshall WL, McNeel D, Miller MD, Mathai SK (2022) ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2\u2013specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: case report. Am Jo Transpl 22:1261\u20131265","journal-title":"Am Jo Transpl"},{"key":"1316_CR291","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2147\/DDDT.S347297","volume":"16","author":"X He","year":"2022","unstructured":"He X, Zeng XX (2022) Immunotherapy and CRISPR cas systems: potential cure of COVID-19? Drug Des Devel Ther 16:951\u2013972","journal-title":"Drug Des Devel Ther"},{"key":"1316_CR292","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.3390\/biomedicines9121867","volume":"9","author":"W Elliott Jr","year":"2021","unstructured":"Elliott W Jr, Guda MR, Asuthkar S, Teluguakula N, Prasad DV, Tsung AJ, Velpula KK (2021) PAD inhibitors as a potential treatment for SARS-CoV-2 immunothrombosis. Biomedicines 9:1867","journal-title":"Biomedicines"},{"key":"1316_CR293","doi-asserted-by":"publisher","first-page":"100403","DOI":"10.1016\/j.esmoop.2022.100403","volume":"7","author":"C Buske","year":"2022","unstructured":"Buske C, Dreyling M, Alvarez-Larr\u00e1n A, Apperley J, Arcaini L, Besson C, Bullinger L, Corradini P, Della Porta MG, Dimopoulos M (2022) Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO open 7:100403","journal-title":"ESMO open"},{"key":"1316_CR294","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3390\/cells11081262","volume":"11","author":"Y-Q Yu","year":"2022","unstructured":"Yu Y-Q, Herrmann A, Thonn V, Cordsmeier A, Neurath MF, Ensser A, Becker C (2022) SMYD2 inhibition downregulates TMPRSS2 and decreases SARS-CoV-2 infection in human intestinal and airway epithelial cells. Cells 11:1262","journal-title":"Cells"},{"key":"1316_CR295","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41375-022-01511-6","volume":"36","author":"T Hueso","year":"2022","unstructured":"Hueso T, Godron A-S, Lanoy E, Pacanowski J, Levi LI, Gras E, Surgers L, Guemriche A, Meynard J-L, Pirenne F (2022) Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis. Leukemia 36:1025\u20131034","journal-title":"Leukemia"},{"key":"1316_CR296","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1080\/10428194.2021.1948031","volume":"62","author":"T Palanques-Pastor","year":"2021","unstructured":"Palanques-Pastor T, Meg\u00edas-Vericat JE, Mart\u00ednez P, L\u00f3pez Lorenzo JL, Cornago Navascu\u00e9s J, Rodriguez Macias G, Cano I, Arnan Sangerman M, Vidriales Vicente MB, Algarra Algarra JL (2021) Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. Leukemia & Lymphoma. 62:2928\u20132938","journal-title":"Leukemia & Lymphoma."},{"key":"1316_CR297","doi-asserted-by":"publisher","first-page":"103960","DOI":"10.1016\/j.isci.2022.103960","volume":"25","author":"JB Weinstein","year":"2022","unstructured":"Weinstein JB, Bates TA, Leier HC, McBride SK, Barklis E, Tafesse FG (2022) A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants. Iscience 25:103960","journal-title":"Iscience"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-023-01316-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-023-01316-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-023-01316-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T23:12:53Z","timestamp":1708297973000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-023-01316-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":297,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1316"],"URL":"https:\/\/doi.org\/10.1186\/s12964-023-01316-9","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]},"assertion":[{"value":"20 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}